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Abstract 
 Current skeletal muscle cell therapy systems have limited effectiveness due to poor 
proliferative capability. The cells are not functional enough to be implanted into a critical size 
muscle defect as a therapy for volumetric muscle loss. Altering in vitro factors, such as mitogens 
and oxygen tension, can have a favorable effect on the cells ability to retain myogenic 
potential. Individual system parameters were characterized through experimental testing of 
culture conditions, media composition, and cell kinetics. Our team designed, engineered, and 
validated a final scalable cell expansion system for proliferating myogenic cells in vitro.  
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Executive Summary 
Introduction 
There is presently a need for tissue engineering of muscle, since the current standard of 
treatment for muscle loss is ineffective. The main associated problem is the loss of functional 
muscle cells, limiting the contractile ability of the engineered muscle tissue [1]. 
Background 
Volumetric muscle loss (VML) is the loss of large volume of skeletal muscle due to 
mostly vehicular accidents and battlefield injuries. Approximately 82% of American soldiers 
injured during battle have at least one extremity injury due to inability to treat the muscle loss 
[2].  Additionally, each year there are at least 20 million traffic related accidents resulting in 
extremity injuries [3]. The current standard of treatment is autologous tissue transfer. However 
this treatment has complications such as donor site morbidity, loss of functionality, and volume 
deficiency. In the case of VML, there are no healthy muscle fibers for the myoblasts to fuse with, 
resulting in non-functional dense scar tissue [4].  
Mitogenic growth factors regulate cell behavior in terms of proliferation and 
differentiation by binding to cell surface receptors and signaling cellular pathways. These growth 
factors are critical for maintaining the mitotic activity of satellite cells, which are essential to the 
regeneration of muscle tissue. Epidermal growth factor (EGF), insulin-like growth factor 1 (IGF-
1), hepatocyte growth factor (HGF), and fibroblast growth factor 2 (FGF-2) have shown to 
increase proliferation and delay differentiation in muscle precursor cells [5].  
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Methods 
Our team considered the important objectives to be the ability to maintain myogenic 
potential, biocompatibility, reproducible, scalable, inexpensive, and quantifiable in decreasing 
order. The goal was to create a scalable system that exhibited a myogenic potential of at least 
30%. In vitro experimentation determined if each growth factor was beneficial to the 
proliferation and myogenic potential of the cells by removing one growth factor per cell culture 
sample. Oxygen tension was characterized by culturing cells with and without growth factors in 
ambient oxygen (~19%) versus 5% oxygen to more closely mimic native muscle tissue. 
Furthermore, adherent and non-adherent cells, which have been shown to exhibit myogenic 
potential until senescence, were plated separately and stained for 5-bromo-2’-deoxyuridine in 
order to proliferation rate in relation to cell behavior. 
In order to quantify the functionality of muscle cells grown in vitro, the myogenic 
potential is measured. Common tests used for quantifying biological data are 
immunocytochemical (ICC) assays. In order to test for functional muscle, neural cell adhesion 
molecule (NCAM) was utilized.. This is because NCAM is present when cell fusion occurs 
during the initial stages of myoblast differentiation [6]. 
Design Alternatives 
 The process focuses on scale-up for alternative designs to apply the characterized 
parameters that improve myogenic potential. The necessary functions of the design are that it 
must retain both the adherent and non-adherent cell populations, provide high surface area to 
media volume ratio, facilitate media exchange, and prevent the cells from terminally 
differentiating. More specific aspects are that it must maintain a myogenic potential of at least 
30% and provide a greater surface area to media volume than 75cm
2
: 8mL. Three possible 
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alternatives were realized to address the predetermined functions: roller bottles, multi-layer 
flasks, and microcarrier systems. 
Results 
Staining for NCAM allowed for determination of the myogenic potential under different 
culture conditions. In a population with no IGF-1, the myogenic index was 21.47  1.02%. When 
compared to the 31.43  1.59% of the positive control, there is a p-value of 0.002. In a 
population cultured in 5% oxygen tension, the myogenic index was 34.56  0.13%. When 
compared to a population at 19% oxygen, there was a p-value of 0.026. In a population without 
FGF-2, the cell surface area was measured to be 28781.67  4425.36 m2. This had a p-value of 
0.031 when compared to the positive control. 
Final Design and Validation 
In order to apply the results of the experiments that address the factors that influence the 
culture system, a final design for the scale-up was chosen through evaluation of the design and 
cost. The roller bottle was chosen, as it is capable of meeting the objectives and constraints of the 
system while being most cost effective. Through the use of a roller bottle, the designed system 
applies the determined growth factor concentrations to a low oxygen environment while 
maintaining both adherent and non-adherent populations in the roller bottle scale-up system.  
Discussion and Conclusion 
The results of these experiments showed the effect FGF-2 and IGF-1 have on the cell 
culture of human muscle cells when compared to the Page lab concentrations. They also showed 
that lowering the oxygen tension has a positive effect on the myogenic potential of the culture. 
There was no statistically significant difference for the characterization of adherent and non-
 viii 
adherent populations; however, further research needs to be done on the proliferation percentage 
overtime from the separate populations. In future experiments it would be useful to test new 
growth factor concentrations such as testing pairs to see what effect one growth factor has on 
another one. 
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1. Introduction 
Tissue engineering is “the combination of cells, engineering, materials, and suitable 
biochemical and physiochemical factors to improve or replace biological functions” (Griffin, 
2009). As the field of tissue engineering progresses, new technologies and techniques are 
developed that allow for advancements in medicine. There is currently a need for tissue 
engineering of muscle (Nerem, 1995). The current standard of treatment for muscle loss is not 
efficient because it has a complication rate of 36 percent (Suh, 2004). Muscle loss can occur in 
people who have suffered traumatic injuries such as car accidents, military injuries, and sports 
injuries (Yong, 2004). A new therapy is needed that will allow for integration of new muscle 
tissue and stimulate proper regeneration, without causing donor site morbidity. For this reason, a 
tissue engineering approach is needed to allow muscle to be produced in vitro from a very small 
biopsy that will not cause additional problems to the patient. 
Recently, tissue engineers have been trying to develop ways to grow functional muscle 
tissue in order to implant it into patients with volumetric muscle loss (VML). The main problem 
encountered is the loss of functional muscle cells, limiting the contractile ability of the muscle 
tissue (Shefer, 2006). Engineered tissue does not function as well as healthy muscle tissue in the 
body and is not currently effective as a therapy.  The proliferative capability of human muscle 
cells decreases with age, making it difficult to achieve a scalable culture that maintains the 
necessary myogenic potential (Shefer, 2006). Another issue is the integration of other body 
tissues, such as vasculature and nervous tissue. Without the integration of these tissues, necrosis 
of the implanted tissue will occur, coupled with an inflammatory response (Levenberg, 2005).  
Research on tissue engineering of muscle started as early as the 1980s (Bischoff, 1986). 
Many potential solutions have been tested, but they lack efficacy. One development that has been 
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a focus is based on the idea of autologous myoblast implantation (Qu, 1998). Unfortunately, the 
injected cells displayed a poor survival rate. Ninety-five percent of the cells died within 48 hours 
(Qu, 1998). In this case, it could be beneficial to culture the cells in vitro since replicating in vivo 
conditions can be a challenge. In vitro factors, such as mitogens, oxygen tension, and plating 
density, can play a large role in how the cells behave and proliferate (Kook et al., 2008, Linkhart 
et al., 1981). Furthermore, most of the research being done is using animal models, as well as 
immortalized cell lines. The clinical application associated with these approaches is limited 
because cell lines are capable of maintaining differentiation potential during extended in vitro 
culture, which is not the case for primary cells (Rothman, 1992). Muscle cells from animal 
models behave differently than human primary muscle cells, and the results will not translate to 
humans (Linkhart et al., 1981).  
Up to this point, there is still much research that needs to be done before tissue-
engineered muscle has a clinical application. There has been little focus on in vitro cell culture 
systems for proliferation and differentiation of human primary muscle cells. In addition, there 
has been limited research on how different environmental factors and media components will 
affect the proliferation and differentiation potential of human muscle cell cultures. 
Concentrations of mitogens present in the media will affect the growth kinetics of the cells; and 
manipulation of these concentrations has potential to produce favorable proliferation and 
differentiation. Oxygen tension and substrate surface properties could also affect cell growth and 
the state of the cells. If the cells are maintained in the progenitor state and terminal 
differentiation is prevented, then the loss of myogenic capability will be reduced. Finally, in 
order to produce a high, clinically relevant number of cells to be used in a therapy for volumetric 
muscle loss, an in vitro system would have to be large-scale and efficient. 
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This report focuses on designing an in vitro cell culture system that selectively amplifies 
the myogenic cells in a human primary muscle cell population. In order to have research 
relevance, the amount of cells with contracting functionality present in the culture must be 
improved. The culture conditions will be characterized by employing combinations of 
differential adhesion, mitogenic stimulation, media components, ambient conditions, and plating 
densities. The team is designing the system to be scaled up so that it could eventually have 
industrial application and be used as a therapy for volumetric muscle loss. 
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2. Background 
This section will discuss the reason behind the need of a cell therapy system and will then 
review the anatomy and physiology of skeletal muscle in detail. Advances in current culture 
techniques will then be discussed as well as composition in media and the recent advances that 
have been made. Finally, the section will close with techniques that are currently in use for the 
gathering of data such as quantification assays. 
2.1 Clinical Need 
Injuries and diseases are the primary cause of muscle degeneration. Severity of muscle 
degeneration ranges from sport related injuries to large muscle defects caused by trauma to 
skeletal muscle. Muscles are injured everyday through exercise, however, in the case of minor 
contusions, strains, or lacerations—this accounts for 55% of muscle injuries—skeletal muscle is 
able to regenerate itself under endogenous mechanisms (Quintero et al, 2009). It is important to 
note, however, that the process of self-regeneration is not 100% efficient. When tissue is torn, 
some scar tissue forms to aid the healing process at the cost of restoring native functionality and 
mechanical properties (Turner & Badylak, 2011). 
 The two types of muscle degenerations that have previously been discussed are causes of 
muscle atrophy. Muscle atrophy is referred to as the wasting or loss of muscle tissue (Dugdale et 
al, 2012). There are numerous causes of muscular atrophy such as aging, stroke, polio, 
malnutrition, etc. The two leading causes of muscular atrophy are volumetric muscle loss and 
muscular dystrophy and both of these conditions are dangerous if not treated properly (Dugdale 
et al, 2012). Muscular dystrophy is a genetic condition and symptoms of this condition may 
appear as early as two to three years of age while others have adult onset (MDA, 2009). More 
than a million individuals in the United States are affected by muscular dystrophy and most die 
by the time they reach 35 due to respiratory infections and cardiomyopathy (MDA, 2009). 
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Neuromuscular diseases affect the nerves that control voluntary muscles initiating muscular 
dystrophy. This is caused by mutations in the gene that encodes the cytoskeletal protein 
dystrophin (Nowak and Davies, 2004). Communication between nerves and muscle deteriorates, 
and as a result muscles weaken and eventually waste away. There are over 40 neuromuscular 
diseases that cause muscular dystrophy. In 2011, the Muscular Dystrophy Association provided 
over $38.1 million to the research for the treatment of this condition. In the same year, $22.9 
million were given for the professional and public health education about muscular dystrophy 
(MDA, 2012). The funds spent on the research and education of muscular dystrophy show the 
need to develop a therapy for the treatment of the disease.  
 Extensive damage to the muscle caused by trauma is also known as volumetric muscle 
loss. Some injuries are so severe that the body cannot repair itself under endogenous mechanisms 
because fibrotic tissue takes over to speed up the healing process. Complete rupture or even 
complete elimination of muscle fibers is mostly due to motor vehicle accidents or ballistic 
wounds (Grogan et al, 2011). For volumetric muscle loss cases, there are very few alternatives 
therefore better treatment options are needed. When there is more than 20% volumetric muscle 
loss, the natural regeneration process will fail resulting in the formation of non-functional scar 
tissue (Turner & Badylak, 2011). Scar tissue takes over the wound site in order to promptly aid 
the healing process. In cases of extensive traumatic injury of skeletal muscle, the likely outcome 
is amputation of the wound site. Most of the injuries that these amputations are performed for are 
from combat-related injuries in the military (Fischer, 2010). Civilians can also sustain extensive 
damage to extremities from motor vehicle accidents, but more funding is being given for the 
treatment of soldiers. Each year, there are 20-50 million people who are involved in vehicular 
accidents resulting in extremity injuries (Hettrich and Browner, 2012). These injuries can lead to 
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compartment syndrome and ultimately to loss of limbs. Compartment syndrome is a condition of 
the limbs where there is insufficient blood supply to the vessels and nerves because of the 
increased pressure within the compartments of the limb (Tiwari et al, 2002). If the area affected 
by the condition is not treated within a short period of time, 6-12 hours, muscles will be severely 
affected ultimately requiring amputation. Compartment syndrome affects approximately 200,000 
Americans each year (McQueen, et al, 2000). Other form of trauma to skeletal muscle include 
battlefield extremity injuries accounting for 82% of combat wounds, furthermore, since the last 
three U.S. military operations, there have been 1700 amputations performed due to extensive 
battle injury to the extremities (Fischer, 2013). Without reconstructive surgery, the number of 
total amputations would be much higher; however, patients who have gone through 
reconstructive surgery often select amputation later on in their lives. They prefer to have their 
extremity amputated as opposed to living their lives with a weak and disabled extremity, which 
can also be the source of chronic pain (Grogan et al, 2011).      
The current gold standard, with limitations, to treat severe volumetric muscle loss is 
autografts, where muscle tissue is taken from a donor site in the body and transplanted to the 
injury site. Autotransplantation is becoming more prevalent in procedures with need of 
functional tissue because there is no risk of disease transmission, and implants tend to generate a 
minimal immune response (Vang, 2006). On the other hand, there are also problems that can still 
arise from autologous grafts such as donor site morbidity and loss of functionality and volume 
deficiency (Suh, 2004). Donor site morbidity plays an important role because the procedure 
creates a second surgical site to remove the amount of muscle needed. Grafts can also get 
rejected or the patient will have a limited restoration of the muscles that were involved in the 
surgery because there is no full recovery (Vang, 2006). The overall complication rate of 
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autologous tissue transfer is 36%. While most complications can be treated, some implants fail 
completely and this is the case of 6% of the individuals that undergo this treatment leading to a 
1% mortality rate (Suh, 2004).Causes of the graft failure range from venous thrombosis to 
necrosis of native tissue (Suh, 2004) The last two complications are the main reason there is a 
clear need for an in vitro cell therapy system for volumetric muscle loss using human skeletal 
muscle cells (Grasman et al, 2012). 
  The development of an in vitro cell therapy system will greatly increase the integration 
of the graft to the host body. In turn, this could decrease necrosis and graft failure. There have 
been advances in culture and formation of skeletal muscle predominantly in the past decade. 
Most research being done is on the targeting and improving of the individual processes of 
progenitor cell proliferation, mobilization, and differentiation (Alberto-Rossi et al, 2010). It is 
important to understand that primary human skeletal muscle cell culture is not efficient enough 
to produce skeletal muscle for the treatment of volumetric muscle loss because at the moment 
there are some aspects of the process that are not fully understood such as being able to retain a 
non-adherent cell population throughout multiple passages. One reason for this problem is that 
cell culture is not done on a large enough surface area where large quantities of cells can grow 
because it is not economically feasible (Rafiq et al, 2013). Another problem with the culture is 
trying to mimic the conditions of the human body. Conditions inside the body are difficult to 
simulate because it is an environment that efficiently changes and adjusts because of satellite 
cells and signaling pathways that orchestrate the regulation of muscle repair (Allbrook, 1981). In 
order to achieve fully functional skeletal muscle, the myogenic index in vitro must be 
comparable to that of the human body. The myogenic index is helpful because it gives an idea of 
how efficiently muscle fibers can be created.  The most efficient in vitro system has only been 
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able to reach approximately 25% myogenic potential (Lee et al, 2000). By reaching a fusion 
index over 30%, a volumetric muscle loss therapy could be developed in the future to treat 
different types of muscular atrophy. 
2.2 Anatomy and physiology of skeletal muscle 
It is important for the anatomy and physiology of the muscle to be understood as the 
importance of volumetric muscle loss therapy is addressed. It is also necessary to understand the 
essential components of skeletal muscle and the regeneration process that plays a role in the 
damage and repairing of the muscle as well.  Before the regenerative process can be fully 
comprehended, the anatomy of the muscle must come into play.  
There are three types of muscles within the human body; but in terms of volumetric 
muscle loss therapy, the focus will remain on the skeletal muscle. Skeletal muscle’s most notably 
characteristic properties that vary it from other muscle types are its striations and multinucleated 
cells (Fox, 2011). The multinucleated tendency is a result of the fibers being formed from the 
fusion of several myoblast cells, which are mononucleated and spindle-shaped. The striations of 
the muscle appear from the presence of sarcomeres, which are the functional units as they repeat 
along the muscle. A sarcomere is a segment of the muscle that creates the banded look of the 
muscle, between thin dark lines that form the borders of the sarcomere called Z-lines. The Z lines 
are a result of the overlapping of the thin myofilaments of adjacent sarcomeres. Actin and 
myosin myofilaments are overlapped on one another in a repeating array to compose the 
sarcomere. Components between the Z-lines consist of the I-bands, which are isotropic, meaning 
“same,” and light colored, and A-bands, which are anisotropic, meaning “not the same” and 
darker in color. Isotropic means that it contains only Actin while anisotropic contains both Actin 
and myosin. The A-bands result from where the myofilaments overlap and the I-bands result 
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from the areas where they do not. To better understand the muscle and its regeneration, it can be 
viewed from large scale to small. 
 
Figure 1: Sarcomere/Basic Unit of Muscle (Tomioka 2009) 
The skeletal muscle is composed of individual fibers, or myofibers, that are able to 
contract when they are stimulated. With the muscle tissue, the fibers contain layers of connective 
tissue that cover and protect the fibers and fascicles of the muscle. The outermost layer of the 
muscle, the epimysium, is made of fibrous connective tissue proteins with the tendons that 
extend around the muscle. Muscle contains type I collagen as its main component, as well as 
type III collagen as a minor component (Light, 1984). This outer layer is often seen as an outer 
sheath of the muscle. Connective tissue from the epimysium extends further into the body of the 
muscle, separating it into various columns called fascicles. Each fascicle is encased in another 
connective tissue sheath known as the perimysium. Working down from the individual fascicle, 
the perimysium is composed of many fibers known as myofibers that again are sheathed 
similarly to the muscle and fascicles in extracellular matrix (ECM). The ECM is important as it 
provides and maintains the structural framework of the muscle. The fibers are surrounded by 
sarcolemma, a thin plasma membrane, and enveloped by a final thin connective layer, the 
endomysium. The fibers are then composed of myofilaments that lead to striations (Fox 2011). 
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Knowing the anatomy and physiology of muscle is important in the understanding of volumetric 
muscle loss and the resulting regeneration for various degrees of injury. 
 
 
Figure 2: Breakdown showing individual muscle components (Peppel 2009) 
As the anatomy and physiology of the muscle are outlined, a microscopic view becomes 
important to recognize. The muscle itself is a result of many differentiated cells known as 
myocytes. Before a cell differentiates into a myocyte, it is first a satellite cell. These are cells that 
have potential to differentiate into various cells within muscle lineages. They are undifferentiated 
cells that reside in a quiescent state between the basal lamina and the plasma membrane of each 
fiber. These cells, and their activation, proliferation/migration, and differentiation, are essential 
in the growth and regeneration of muscle. The need for regeneration is a daily occurrence, but 
the degree to which it is necessary varies with the injury. Typical small injuries that occur on a 
more common basis such as simple cuts and tears can regenerate on their own without the need 
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for autograft or assistance. With smaller scale injuries that do not result in volumetric muscle 
loss, regeneration is possible naturally by the body. Aside from small, daily regenerations from 
exercise and similar acts, the need for a therapy for volumetric muscle loss is a common result of 
sports injuries that cause the muscle to shear, results in tearing of the myofibers and connective 
tissues. To address this, the process is typically characterized by destruction, repair, and 
remodeling (Huard and Peng, 2004).  
2.2.1 Muscle Regeneration 
The regeneration process begins with an injury that exposes the intracellular contents to 
the extracellular environment. Typically, injuries occur due to the tearing of myofibers and 
connective tissues. An injury is the breaking up of the myofibrils into individual sarcomeric 
units, disrupting the continuous nature of the sarcolemma, as well as the disruption of the 
mitochondria and the sarcoplasmic reticulum (Carlson, 1989). Regeneration is often 
characterized by hematoma formation, muscle tissue necrosis, degeneration, and inflammatory 
cell infiltration. As a result of this, the activation of calcium-dependent protease leads to the 
contraction band of cytoskeletal proteins forming to prevent complete destruction of the 
myofibers at the site of injury. After this, the chemotactic recruitment of neutrophils and 
macrophages occurs. These neutrophils and macrophages are able to release cytokines to 
amplify, or suppress depending on the stage, the inflammatory response. They are used to digest 
necrotic fibers and cellular debris by phagocytosis that result from the injury. With the amplified 
inflammatory response and signals from the environment, the recruitment of satellite cells begins 
(Charge, 2004). Once the quiescent satellite cells are exposed to the signals from the inflamed 
environment, the activation of their proliferation and removal from quiescence is characterized 
by the expression of Myf5 and MyoD, two myogenic regulatory factors (Charge, 2004). As the 
cells are recruited, there are two phenotypes of macrophages that promote different behaviors in 
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the precursor, satellite, cells. The M1 phenotype phagocytose the necrotic tissue while promoting 
satellite proliferation. The M2 phenotype remodels the tissue further along, promoting 
proliferation, growth, and differentiation (Turner & Badylak 2011).  
After the inflammation period, the satellite cells begin to migrate to the site of injury to 
begin the repair phase of regeneration as the muscle precursor cells begin to proliferate. When 
the cells exit the cell cycle, they begin to differentiate into myoblasts. With this, the myoblasts 
that are a result of differentiated satellite cells begin to fuse with myofibers that have necrosed in 
an effort to prevent complete degeneration of the non-functional fibers that are already there. 
When this is not possible, the myoblasts mature and fuse to form functional myotubes. While the 
differentiation and fusion are occurring, there is also proliferation of fibroblasts that produce the 
ECM necessary for the muscle to form on as a scaffold. The fibroblasts respond to the site of 
inflammation and are located in close proximity of the satellite cells and muscle fibers. The cells 
proliferate and differentiate as a means of creating an ECM that encapsulate the muscle fibers. 
After migration to the site of injury, fibroblasts differentiate into myofibroblasts and deposit 
ECM proteins, resulting in collagen deposits and connective tissue formation which promotes 
tissue fibrosis (Burks, 2011). In an in-vitro study, fibroblasts have the potential to form an ECM 
on which muscle may form.  Due to environmental factors, fibroblasts are observed to proliferate 
with a quicker population doubling time than satellite cells. Unlike in vivo where it is naturally 
regulated¸ when compared side by side, a culture of the two cells would show a greater rate of 
proliferation for fibroblasts. If the fibroblasts are allowed to over proliferate, dense scar tissue 
forms. In native muscle, the over proliferation of fibroblasts does not occur. On a smaller scale, 
the dense fibrous connective tissue that remains is not always harmful to the individual. When 
the injury leads to greater generation of scar tissue and overgrowth of connective tissue, it 
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impedes the regeneration and leads to incomplete restoration of functionality. Once remodeling 
is complete, the satellite cells that did not differentiate migrate between the newly formed basil 
lamina and membrane of the new muscle and reenter a quiescent state as with the mature muscle 
(Peng and Huard, 2004). 
In the event of an injury of a larger scale or degenerative disease, there is a need for a 
large quantity of cells and matrix to replace what is lost. A volumetric muscle loss therapy 
becomes necessary for increased regeneration and functionality of the injured muscle.  
2.3 Cell Cycle and Culture Conditions   
 When satellite cells are activated, they enter the cell cycle and progress through 
myogenesis which is the formation of muscle tissue. The cell cycle is a process of events through 
which cells go through that involve division and duplication. The final result of the cycle is 
known as a daughter cell, which is an independent split from the original cell that contains its 
own nucleus and duplicated DNA. The cycle of cell division consists of four phases known as 
Gap 1 (G1), Synthesis (S), Gap 2 (G2), and Mitosis (M). The first phase, G1, is beginning of 
division where the cell begins to grow and enter the S phase. This second phase is characterized 
by the replication of the cell’s DNA. Once DNA is replicated, the cell moves on the G2 phase 
where it continues to increase in size until division. As the cell reaches the final phase, the M 
phase, growth stops. With this, the cell divides in two, each with their own DNA and nucleus, 
into two independent cells (Cooper, 2009).  
In order to differentiate, the cell must exit from the cell cycle which occurs before the S 
phase.  Signal pathways that regulate cell activity drive proliferation and differentiation; and for 
differentiation to occur, the proliferation pathway must be inhibited.  Throughout the cell cycle, 
myogenic transcription factors are expressed sequentially in order to regulate specific stages of 
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myogenesis. These transcription factors initiate the transcription of a specific gene regulating cell 
behavior. Upon inhibiting proliferation, myoblasts express myogenic transcription factors, such 
as MyoD and Myf-5; and the increased expression of MyoD and muscle-specific genes induces 
differentiation. Subsequent transcription factor expression of myogenin initiates fusion of 
differentiated myoblasts into multinucleated myotubes. Once terminally differentiated, cells 
cannot reenter the cell cycle (Wood, 2013).  
The increased expression muscle-specific genes are essential to myoblast differentiation; 
however, mitogenic growth factors can suppress differentiation by promoting proliferation 
within myoblasts through mitogen-activated protein kinase (MAPK) pathways (Kitzmann, 
1998). More specifically in mammalian cells, mitogens activate the extraceullular signal 
regulated protein kinase (ERK) cascades, ERK1 and ERK2, in order to induce transcription of 
cyclin D1 which is required for entry into the S phase of the cell cycle (Robinson, 1997).  
2.3.1 Mitogenic Growth Factors 
 Mitogenic growth factors regulate cell behavior in terms of proliferation and 
differentiation by binding to cell surface receptors signaling cellular pathways.  In order to 
control cellular activity, growth factors either promote or inhibit proliferation by promoting cells 
to exit or enter quiescence, respectively. Mitogenic growth factors are critical for maintaining the 
mitotic activity of satellite cells and are essential to the regeneration of muscle tissue. 
Furthermore, mitogens can be released from cells through signals to surrounding cells as a 
paracrine mechanism or to itself as an autocrine mechanism (Hayashi et al., 2000). 
Insulin-like Growth Factor (IGF-1) promotes myoblast proliferation. Upon 
differentiation, IGF-1increases hypertrophy by promoting differentiation into myocytes and 
fusion into multinucleated myotubes. Studies have shown mice lacking IGF-1 and IGF-2 
expression undergo limited hyperplasia and are unable to produce sufficient muscle mass to 
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function. Alternatively, as the result of up regulating IGF-1 expression, muscle regeneration and 
hypertrophy significantly increased (Duan, Gao, & Ren, 2010). Under normal oxygen supply, 
19% ambient oxygen, IGF-1 expression promotes proliferation in cells; however, in the presence 
of a reduced oxygen environment simulating native muscle oxygen tension, IGF-1 promotes 
myoblast differentiation (Duan, Gao, & Ren, 2010). In an experimental study investigating the 
effect of hypoxia on the myogenic capacity of insulin-like growth factors, 300ng/mL of IGF-1 
was shown to have a direct increase to the differentiation of C2C12 cells at normoxia while 
having an inhibitory effect to differentiation at hypoxia. Furthermore, 300ng/mL of IGF-1 was 
shown to increase proliferation rate of C2C12 cells at normoxia and nearly triple the proliferation 
rate at hypoxia as shown in Figure 3 below. Data are expressed as mean ± standard deviation for 
a sample, n=3, and statistical differences are noted as * for p<0.05 and ** for p<0.01 (Ren et al., 
2010). 
 
Figure 3: The Effect of Media with and without IGF-1 on the Proliferation and Differentiation of C2C12 Cells at 
Normoxia and Hypoxia (Ren et al., 2010) 
Hepatocyte Growth Factor (HGF) induces quiescent cells to enter the cell cycle causing 
DNA synthesis and promoting cell proliferation by activating these quiescent cells to enter the S-
phase of the cell cycle (Gal-Levi et al, 1998). Upon satellite cell proliferation, the cell stimulates 
further production of HGF with potential of increasing local concentrations of HGF. As the 
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concentration of HGF increases, there is potential for the cell to return to quiescence and 
resultant production of myostatin due to high concentration of HGF (Yamada, 2010). 
Furthermore, HGF significantly enhances cell proliferation when used in conjunction with 
Fibroblast Growth Factor-2 (FGF-2) (Deasy et al., 2001). The mitotoic effect of FGF-2 and the 
FGF family can be further enhanced by using the growth factor in combination with the optimal 
concentration of 10ng/mL of HGF (Sheehan, 1999). In an experiment study investigating the role 
of HGF, myoblast fusion was demonstrated to decrease from 30% to 0% as HGF concentration 
increased from 0ng/mL to 100ng/mL. At the maximum concentration of HGF, there were no 
multinucleated myotubes present in the culture, and the cell number had triple in comparison to 
0ng/mL of HGF as shown in Figure 4 below. Data are expressed as mean ± standard deviation 
for a sample, n=4. There are statistical differences between means denoted as different letters (a, 
b, c, and d) for p<0.05 (Hayashi, 2000). 
 
Figure 4: Dose-Dependent Effect of Recombinant Human HGF on Proliferation of Myoblasts (Hayashi, 2000) 
Fibroblast Growth Factor-2 stimulates proliferation and migration within cells and can 
lead to an abundance of satellite cell-like myoblasts instead of terminally differentiated 
myotubes. Researchers have suggested that FGF-2 may exhibit an indirect inhibition to 
differentiation and is often used in combination with other growth factors in order to form fused 
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myotubes. Naturally in the body, FGF-2 is stored in the extracellular matrix and is released 
during the inflammatory stage of muscle regeneration in vivo prompting the first satellite cells to 
begin proliferating (Husmann, 1996). 
Epidermal Growth Factor (EGF) stimulates cell proliferation through up regulating the 
intake of nutrients into cells.  Furthermore, EGF has potential application in organ regeneration 
and wound healing as it enhances the proliferation and migration of cells (Wells, 1999).  There is 
potential for increased proliferation and differentiation capability of cells as the EGF binding to 
the EGF-receptor activates mitogen-activated protein kinases (Jeong, 2013). EGF has been show 
to increase the proliferative capable of myogenic cells as in one experimental study where cells 
cultured in EGF exhibited an 85% proliferation rate compared to 77% without EGF. With the 
presence of EGF, more cells entered the cell cycle and proliferated (Deasy et al., 2002). 
2.3.2 Media Composition 
Ham’s F-12 and Dulbecco’s Modified Eagle Medium can be combined to provide cells 
with the essential nutrients, all 13 essential amino acids, and seven non-essential amino acids. 
This combination provides high amino acid content with a highly enriched nutrient content. 
FetalClone III (FCIII) serum is used in proliferation media within cell culture by providing the 
cells with essential components including glucose, growth factors, nutrients, vitamins, and 
hormones. Proliferation media is supplemented with IGF-1, HGF, FGF-2, and EGF to further 
preserve the mitotic activity of the cell population. A supplement of L-glutamine is added to the 
media drives proliferation and cellular activity (Huard & Jankowski, 2004). In order to induce 
differentiation, the media is transferred in media containing 2% adult horse serum and 1% 
insulin, transferrin, and selenium (ITS) (Huard & Jankowski, 2004). Low-serum media provides 
cells with a necessary supplement of ITS. Insulin is a necessary hormone for cells to progress 
through the cell cycle, transferrin provides iron to the cells, and selenium helps cells protect 
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against oxidative stresses (Van der Valk, 2010).The removal of mitogens prevents signaling of 
the MAPK pathways and results in expression of muscle specific genes for differentiation 
(Robinson, 1997). 
2.4 Measuring Myogenic Potential 
Many different assays exist that allow researchers to quantify data and produce workable 
results. In order to quantify the functionality of muscle cells grown in vitro, the myogenic 
potential is measured. Researchers identify antigens specific to functional myocytes and perform 
targeted assays to determine the percentage of functional cells present.  
2.4.1 Neural Cell Adhesion Molecule Immunocytochemistry Assay 
 Common tests used for quantifying biological data are immunocytochemistry (ICC) 
assays. This involves using antibodies to target and mark a desired antigen. The presence of the 
antigen can be visualized by using fluorescent tags on the antibodies along with fluorescence 
microscopy. This is straightforward for extracellular antigens, but in order to tag intracellular 
antigens, the antibodies need to cross the cell membrane. For this to be possible, the cells must 
first be permeabilized using a detergent, such as Triton X-100 or Tween-20 (Gaster et al 2001).  
More specifically, ICC can be used to identify cells that have differentiated by targeting antigens 
unique to the differentiated cells. In order to visualize contractile muscle cells, researchers need 
to target antigens that exist only in differentiated myotubes. A common antigen to target is neural 
cell adhesion molecule (NCAM) (Gaster et al. 2001). NCAM is a satisfactory differentiation 
marker because it is expressed relatively early (within four days), allowing it to be stained for 
after less time (Rutishauser 1988). The figure below shows human skeletal muscle cells stained 
for NCAM. When used in conjunction with DAPI, researchers are able to visualize functional 
myotubes as multiple nuclei aligned on NCAM positive cells. 
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Figure 5: NCAM staining of human skeletal muscle 
2.4.2 Desmin Staining 
 Another assay that can be used to visualize differentiation is desmin staining. Desmin is 
one of the first proteins expressed during the early stages of differentiation. It has been shown 
that desmin is expressed before MyoD expression (Costa et al. 2004). This expression will 
disappear over time making it more difficult to accurately analyze the percentage of 
differentiation in the culture (Cooper et al. 2004). Desmin is located all over myotubes, but tends 
to be at the highest concentration in the Z line. 
2.4.3 Nuclear Staining 
 In order to calculate the myogenic index, one must first be able to visualize the nuclei of 
the cells present in the culture. A common technique involves using a fluorescent nuclear stain, 
4’, 6-diamidino-2-phenylindole (DAPI). DAPI is a blue-fluorescent nucleic acid stain that 
associates with the adenine-thymine cluster and allows for visualization of the DNA in the 
nucleus of a cell (Invitrogen 2006). 
2.4.4 Calculating the Myogenic Index 
 Once the cells are stained, the myogenic index can be calculated. In the Page lab, the 
myogenic index is calculated using the following formula: 
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This formula is appropriate because differentiated and fused myotubes will have a high 
expression of NCAM. Therefore, if a cell tests positive for NCAM, and contains multiple nuclei, 
it is counted as a myogenic cell. The myogenic index is a ratio of the myogenic cells to the total 
number of cells. 
2.5 Measuring Proliferation 
One way of measuring cell proliferation is to perform a 5-bromo-2’-deoxyuridine (BrdU) 
assay. This assay uses specific antibodies to insert fluorescent tags into cells that are dividing, by 
binding with newly synthesized DNA. BrdU is an analogue to the nucleoside thymidine 
(Waldman et al. 1988). In culture, BrdU will replace thymidine in the newly forming DNA 
during the S-phase of the cell cycle. Because the population doubling time for human skeletal 
muscle cells is around 40 hours (see Appendix B), the BrdU labeling agent should be 
incorporated in the culture for 48 hours. This is just enough time to allow all proliferating cells to 
go through only one complete cell cycle. The cells can be fixed and stained to visualize cell 
proliferation. Anti-BrdU antibodies can be added to the culture that will attach to the BrdU 
antigen. Then, a secondary antibody that targets the primary one can be introduced. This 
secondary antibody contains a fluorescent tag, which can be viewed under a fluorescence 
microscope, when excited by the appropriate fluorophore. Any fluorescence that is seen indicates 
a cell that has replicated its DNA and is proliferating (Kulldorff et al. 2000). 
For comparison, a fluorescent nuclear counterstain can also be added to visualize the total 
number of cells in the culture. By comparing the fluorescence of the nuclear stain to that of the 
BrdU tag, the percentage of cell proliferation can be determined. By testing the adherent and 
non-adherent populations separately, it is possible to determine the significance of the non-
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adherent cells, and their relationship to the cell cycle.  
2.6 Recent Advances Volumetric Muscle Loss Therapy 
There is a clear need for refined culture techniques of human skeletal muscle cells in 
order to further the development of a regenerative cell therapy process. Great improvements have 
been made for the understanding of the mechanisms that control cell proliferation and 
differentiation. A recent study showed that within a satellite cell population, there are slow-
dividing and fast-dividing cells. These two populations have different characteristics and each 
population was studied. It was shown that slow-dividing cells possess long-term self-renewal 
ability whereas the fast-dividing cells tend to terminally differentiate after a couple doublings. 
The importance of this study was that the slow-dividing cell cultures showed an increased 
myogenic potential (Ono et al, 2012). Various types of substrate stiffness have shown to have an 
effect on the myogenic and regenerative potential of muscle cells. Research has demonstrated 
that there is a direct correlation between the stiffness of the substrate and the proliferation rate of 
the cells showing that a higher stiffness leads to proliferation (Engler et al, 2004).  
 Stem cell microenvironments tend to be hypoxic, a low oxygen level compared to 
ambient. It has been suggested that treating cells under hypoxic conditions will trigger response 
from satellite cells resulting in the adoption of a quiescent state where they proliferate at a faster 
preventing them from differentiating (Koning et al, 2011). What Koning and his colleagues 
hypothesized for this experiment was that hypoxia improves proliferation and differentiation of 
stem cells. Another way to maintain a muscle derived cell’s stemness is to keep it in suspension 
or in their spheroid form. Several studies have tried to achieve this and have succeeded. A study 
done in Germany has come up with a protocol to culture “myospheres” using myopshere-
growing media. This media was composed of Dulbecco's Modified Eagle's Medium 
(DMEM/F12, ratio was not specified), 20% Fetal Clone Serum (FCS), basic Fibroblast Growth 
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Factor (bFGF) 5 ng/ml, and 1% P/S (Wei et al, 2011). The media was kept at humidified of 5% 
CO2 in air. Using this culture technique allowed the researchers to keep the cells in their spheroid 
condition for at least five months allowing the cells to go through over 40 population doublings 
(Wei et al, 2011). Their study concluded that myosphere-derived progenitor cells could be 
maintained proliferatively active in vitro for more than 20 weeks and passaged at least 18 times, 
despite an average donor-age of 63 years. 
Much work has been done on the growth media composition and its components. The key 
components of the media are the growth factors such the ones that the Page Lab uses (EGF, IGF-
1, HGF, and FGF-2). It has been shown that other growth factors such as Mechano Growth 
Factor (MGF) can further help the to induce the growth and hypertrophy in mechanically 
stimulated or damaged muscle. MGF or IGF-1Ec is a variant of the IGF-1 and was shown to 
have an increase by 30% in the myogenic potential of human myoblasts when compared to IGF-
1 (Kandalla et al, 2011). Fusion indices have been increasing due to better culturing techniques 
and a study was done at the University of Pittsburg where a myogenic index of 25% was 
achieved from a female rat model compared to the rest of the preplates, which achieved no more 
than 15% myogenic index (Jankowski, 2004). The differentiation media was composed of 
DMEM containing 2% horse serum and 1% penicillin/streptomycin and containing different 
concentration of suramin (0, 1, 10, 100μl/ml). Suramin is an antifibrotic agent that improves 
muscle recovery by antagonizing transforming growth factor–beta1 (TGF-β1), a fibrotic 
promoter (Jankowski, 2004). 
  
 23 
3. Project Strategies 
The primary goal of this project is to design and optimize an in vitro cell culture system 
that selectively amplifies myogenic cells in order to extrapolate a prototype for the tissue 
engineering of contractile muscle tissue.  The purpose of this chapter is to explain the process 
used in identifying and defining the objectives and constraints of the design.  After evaluating the 
objectives and constraints, the group revised the initial client statement and outlined the project 
approach.    
3.1 Design 
 In every design, the three stakeholders consist of the client, the user, and the designer.  
For this project, the client was Dr. Raymond Page, the users were researchers or graduate 
students experimenting with the application of functional muscle tissue engineering, and the 
designers consisted of Brishell Aquise, Kyle Bonaccorso, Jeffrey Ducki, and Andrew Lamb.     
3.2 Initial Client Statement 
 The following statement is the initial client statement provided to the team by the client, 
Dr. Raymond Page.  Based on the statement, the team shaped objectives and constraint necessary 
for reaching the desired goals. 
“Currently, the laboratory uses extruded fibrin microthreads with human 
skeletal muscle derived cells seeded onto the surface and transplanted into 
SCID mouse skeletal muscle injury models to study the effect of various cell 
derivation and culture methods on functional tissue regeneration.  One of the 
limitations in primary human skeletal satellite cell and myoblast culture in 
vitro is the loss of myogenic potential with each subsequent passage.  Some of 
this loss may be attributed to contamination of fibroblasts in the culture, and 
therefore selective amplification of the fibroblasts over the myoblasts, given 
the culture conditions employed.  The laboratory has recently discovered a 
culture system based factors and selective cell adhesion characteristics that 
enable the propagation of mostly myogenic cells which on specific growth are 
capable of differentiating into myocytes upon removal of mitogens from the 
culture medium.   
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In order to apply this technology at large and economical scale, the detailed 
growth factor dependent and substrate physical/biosignaling properties must 
be defined, and optimized.  The goals of this project are: 
 
 Design an in vitro cell culture system that selectively amplifies 
myogenic cells by employing combinations of differential adhesion, 
selective mitogenic (growth factor) stimulation and controlling 
ambient oxygen.  
 Determine the growth kinetics and cell purity, and differentiation 
potential of the myogenic cell population with increased time in vitro 
according to individual system design parameters.  The myogenic 
potential (measured by the fusion index) for the cells at the end of the 
culture period must be at least 30%. 
 Employ individual parameter optimization results to engineer, build, 
and test a final ex vivo myogenic cell expansion system.   
 Extrapolate (scale up) prototype system to enable replacement of 20 
ml of muscle tissue from cell derived from a 200 µl skeletal muscle 
biopsy.” 
 
3.3 Objectives 
 In order to accomplish the project goals, the team designed the following objectives. The 
objectives were to be inexpensive, biocompatible, quantifiable, scalable, reproducible, and be 
able to maintain a myogenic potential of greater than 30%.  Each of the objectives was listed in 
an Objectives Tree along with sub-objectives, as shown in Figure 6 below, and they were ranked 
in order of significance using a Pairwise Comparison Chart. 
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Figure 6:  Objective Tree including objectives and sub-objectives. 
 
Inexpensive: Muscle tissue engineering requires a cell culture system that better preserves the 
myogenic potential of cells through proliferation to large populations. There will not be a 
feasible commercial application for the system if the price of the process is not affordable by a 
combination of volumetric muscle loss patients and insurance providers. The feasibility of the 
cost will be determined based on the cost benefit analysis in selecting the final design. 
Biocompatible: The cell culturing process uses human primary cells; and therefore all ambient 
conditions, substrates, and media compositions has to mimic the physiological environment of 
human primary muscle cells and be non-cytotoxic.   
Quantifiable: The design needed to be quantifiable in order to measure myogenic index and 
compare the effect of design parameters by counting cells and calculating the myogenic potential 
of cells. 
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Scalable: In order to have commercial application, a final expansion system requires a high 
surface area, ease of media change, and elimination of exposure and risk of contamination. A 
scalable system reduces the necessary resources, expenses, size restrictions, and other facts that 
limit the feasibility of increasing the amount of cell within the culture process. 
Reproducible: The specific protocol and cell culture system design had to be easily and feasibly 
reproducible in order to have application in improving functional muscle tissue engineering. 
Maintain myogenic potential: Maintaining a myogenic potential of greater than 30% was 
significant in order to advance the clinical relevance of the process. Engineering muscle tissue 
with enough potential to fuse into myotubes after increased time in vitro is critical to creating 
research applications. In order to achieve this myogenic potential, sub-objectives of 
characterizing media composition, ambient conditions, differential adhesion, and plating 
densities needed to be completed. 
 Pairwise Comparison Charts, as shown in Table 1 below, rank objectives by comparison 
each of them against each remaining objective.  If the objective is more important than the other, 
it receives a score of 1.  If the objective is less important than the other, it receives a score of 0, 
and ties result in a score of 0.5. 
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Table 1: Pairwise Comparison Chart 
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Inexpensive X 0 1 0.5 0 0 1.5 4 
Biocompatible 1 X 1 1 1 0 4 1 
Quantitative 0 0 X 0 0.5 0 0.5 5 
Scalable 0.5 0 1 X 0 0 1.5 4 
Reproducible 1 0 0.5 1 X 0 2.5 3 
Maintain 
Myogenic 
Potential 
1 1 1 1 1 X 5 2 
 
 After evaluating the objectives, the team decided the objectives ranked in decreasing 
significance are: 
1. Optimize Myogenic Cells 
2. Biocompatible 
3. Reproducible 
4. Scalable 
5. Inexpensive 
6. Quantifiable 
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3.4 Constraints 
 The team identified and compiled a list of constraints that the design could not violate.  
These constraints were expressed within the initial client statement and discussed with the Dr. 
Raymond Page before finalized: 
 The cell culture process, media, and other components must be biocompatible 
with the human primary cells in use. 
 The cell culture process must consist of sterile technique, sterile equipment, and 
fit inside the sterile biosafety cabinets and incubators. 
 Incubator space limited the size of the system as the lab contained four incubators 
shared with several other project groups. The dimensions within the incubator 
were 2’x18”x19.5” split into three shelves of 7”x18”x19.5”. 
3.5 Revised Client Statement 
 After meeting with the client and reviewing the ranked objectives and constraints, the 
team revised the initial client statement to be as follows: 
 Design a biocompatible and quantifiable in vitro cell culture system that 
characterizes individual parameters of adherent and non-adherent cell kinetics by 
employing combinations of differential adhesion, media composition and supplements, 
ambient conditions, and plating densities.  Characterize an environment to increase 
proliferation and selectively amplify myogenic cells in the culture to exhibit a myogenic 
potential of at least 30% in order to engineer a scalable cell expansion system with 
increased time in vitro. 
3.6 Financial Approach 
In order to ensure that the project spending is controlled and will stay within the total 
budget, potential expenses were estimated based on current pricing. The main expenses will be 
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on different media components to be used in the research. All of the media components are 
purchased from VWR International with the exception of the growth factors, which are 
purchased from PeproTech. The cost for making 500 mL of DF12 complete media with growth 
factors was calculated based on the prices, and is shown below. 
Table 2: Cost breakdown for medium 
Component Amount/500mL Commercial Price Price/500mL 
Amount Price 
DMEM 270 mL 500 mL $16.34 $8.82 
HAMSF12 180 mL 500 mL $16.41 $5.91 
FCIII 50 mL 500 mL $164.98 $16.50 
L-glutamine 0.1578 g 25 g $60.18 $0.38 
FGF-2 [4.0 ng/mL] 2.000 µg 500 µg $720.00 $2.88 
HGF [2.5 ng/mL] 1.250 µg 500 µg $2,880.00 $7.20 
EGF [10 ng/mL] 5.000 µg 500 µg $195.00 $1.95 
IGF-1 [5.0 ng/mL] 2.500 µg 100 µg $195.00 $4.88 
Total       $48.52 
 
The total cost to make 500 milliliters of media is $48.52. Estimating that the research required 
about 2,000 milliliters, the total expense for media was around $194.08. Because the media 
components were given donated by the Page lab, the expense was not taken from our budget. 
There was also a $100 expense to cover lab materials being purchased by Worcester Polytechnic 
Institute. Some of these materials include pipets, micropipette tips, flasks, well plates, and 
conical tubes. In addition, a gas tank was purchased from AirGas for $160.35, and roller bottles 
were purchased from Thermo Scientific for $220.64. The total budget for this project is $624. 
The remainder of the budget was used for support expenses. 
3.7 Experimental Approach 
 The experimental approach includes a description of the cell culturing methods, 
experiments, and the financial approach to the completion of the project.  The experimental 
 30 
approach identifies important challenges and the technical strategies in overcoming them in order 
to meet the project objectives.  
3.7.1 Cell Culture Methods  
 The cells used in the project were hSkm, human primary muscle cells. The cells were 
taken from a skeletal muscle biopsy of a 58yr old woman, and cell line derivation was 
completed. In order to isolate the myogenic cells for culture, the Page Lab used a modified pre-
plating technique removing the fibroblasts by selective adhesion. For cell culture, the DF12 
complete media consisted of Dulbecco’s Modified Eagle Medium and Ham’s F12 at a 60:40 
ratio containing 10% FCIII and 4mM L-glutamine. The media contained the growth factors: 
HGF, IGF-1, EGF, and FGF-2 at current Page Lab concentrations of 2.5ng/mL, 5.0ng/mL, 
10ng/mL, and 4.0ng/mL, respectively.   
 Cell culture media often contains antibiotics in order to reduce the risk of contamination; 
however, the use of antibiotics can result in antibiotic resistant microorganisms or have a 
negative effect on cellular behavior (Valk et al, 2010). Since this media does not contain 
antibiotics to protect the culture from contaminants, the importance of sterile technique increased 
as the cell culture had no resistance to contaminants. The team had to incorporate sterile 
technique into every aspect of the subculturing process. Everything entering the hood was wiped 
with 70% ethanol. When opening containers and maneuvering inside the Biological Safety 
Cabinet, the team took care not to cross hands or non-sterile objects directly above open 
containers. 
 The team started cell culturing by thawing 500,000 hSkm 1201 P4 into 2 T75 flasks 
according to the protocol in Appendix A. Following thawing, the media was replaced every 48 
hours with fresh media while retaining all the non-adherent cells, and the cells were passaged 
with 0.05% Trypsin each time the cell population reached 70% confluence, as described in 
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protocols in Appendix A. In order to retain the non-adherent cells, the media in active culture 
was pipetted into a 15mL conical tube, and the cells were pelleted using a Clinical 50 centrifuge. 
The pellet was broken up by repeat pipetting, resuspended in media, and replated in a new 
vessel, and adherent cells were passaged using 0.05% Trypsin to release cells. After 
trypsinization, non-adherent cells were pelleted, resuspended in media, and replated in a new 
vessel. The passage rate, type or size of vessel, and plating densities varied depending on the 
current experiment as described in Section 3.6.3 Experiments for Characterizing Individual 
System Parameters. 
3.7.2 Quantification Process 
 A quantification process must be standardized with specific parameters in order for a 
design to be accurately evaluated and return statistically significant resu1lts. In order for results 
to be statistically significant, T-tests were used to analyze whether there was a statistically 
significant difference between results for a test group and a control group. If the null hypothesis 
was not rejected, conclusions were drawn concerning the individual system parameter isolated in 
the experiment. The team used an immunocytochemistry assay staining for NCAM to measure 
myogenic index and myogenic potential, as previously described in Section 2.4.1, after cells 
were plated into well plates and differentiated in DF12 complete media containing 2% HS, 1% 
ITS, and no growth factors. Furthermore, the team counted cells using a hemocytometer in order 
to determine proliferation rates. After performing the assays, the cells were imaged using a Zeiss 
inverted epi-fluor microscope and analyzed using AxioVision software. Three images were taken 
per stained well, and T-tests evaluated the myogenic indexes of each sample against the control 
and other samples for significant differences. Also, the magnification of the microscope was set 
at 20x for all images. In order to calculate the myogenic index precisely, myotubes were 
specifically defined as two or more NCAM positive nuclei fused into a multinucleated cell and 
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aligned in a central axis across the cell. The resultant myogenic index was calculated as 
previously described in 2.4.4 Calculating the Myogenic Index. When staining for NCAM and 
BrdU, one stained control removed the primary antibody and the other removed the secondary 
antibody. This displayed the non-specific staining that was ignored within the experimental 
groups. Finally, qualitative images taken during cell culture were analyzed with AxioVision 
software.  
3.7.3 Experiments for Characterizing Individual System Parameters 
 In order to characterize individual system parameters, experiments were set up isolating 
growth factor combinations, adherent versus non-adherent cell behavior, and oxygen tension to 
determine the effect on myogenic potential of human primary cells. These experiments 
determined an effective environment for maintaining a myogenic potential above 30%. A final 
scaled-up expansion system incorporated the experimental results in order to apply effective 
culture system parameters. 
Growth Factor Characterization Objective:  
The primary objective in this study was to determine if each growth factor is beneficial to 
the culture system in increasing proliferation and myogenic potential.  The secondary objective is 
to determine the magnitude of the effect of removing each individual growth factor compared to 
the others.  This information will determine further growth factor characterization studies.   
Hypothesis:   
The removal of each growth factor should decrease the proliferation rate of cells since all 
the growth factors are used in order to preserve the mitotic capacity of cells and prevent them 
from leaving the cell cycle. Similarly, removing growth factors should decrease the number of 
non-adherent cells since they have been shown to preserve proliferative capability and myogenic 
potential. 
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Experimental Design: 
 The initial growth factor study consisted of making four separate complete proliferation 
media solutions by removing one growth factor while maintaining the current Page Lab 
concentrations for the remaining three. In addition, the study included a positive control 
containing the current Page Lab concentrations for all four growth factors and a negative control 
containing no growth factors. Six identical starting populations of 50,000 cells were plated into 
six T25 Nunc flasks in complete proliferation media each with the respective media as shown in 
Figure 7 below. Media was routinely changed, and cells were passaged at 70% confluence in 
order to characterize the effect of each growth factor on the adherent and non-adherent cell 
behavior. Cell counts were taken for adherent and non-adherent cell populations upon passage in 
order to calculate population doublings and compare proliferation rates between populations. 
After passaging, cells were plated at 20,000 cells per well in a 4 well plate, proliferated for 24 
hours in proliferation media containing the specific growth factors, and switched to 
differentiation media. After differentiating for 4 days, the cells were stained for NCAM using 
Immunocytochemistry, and the myogenic index was calculated as described in calculating the 
myogenic index. 
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Process Flow Diagram:     
 
Figure 7: Growth Factor Characterization Study 
Oxygen Tension Characterization Objective:   
The objective of this experiment is to determine if low oxygen amplifies or reduces the 
effect of the growth factors.  Furthermore, the study without the growth factors will determine if 
the oxygen tension has a direct effect on the proliferation and differentiation of human primary 
cells. 
Hypothesis:   
The hypothesis is that there will be a significant difference between proliferation, 
measured by an increased cell count, and differentiation, measured by NCAM staining, behavior 
of the native and ambient oxygen tension cultured cells (Kook et al., 2008).   
Experimental Design: 
 In order to determine the effect of oxygen tension on cell behavior, two identical starting 
populations of cells will be plated at 250,000 cells per T75 Nunc flask in current Page Lab 
growth factor concentrations and will be cultured with routine media change and passaging using 
routine protocols as previously described in subculturing cells. One of the flasks will be cultured 
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in a low oxygen cylindrical chamber at 5% oxygen replicating native oxygen tension of skeletal 
muscle within the body. In order to control the oxygen level of the chamber, an air supply tank 
containing 5% CO2, 5% O2, and balance nitrogen was purchased from Airgas. Following each 
media change on days 3 and 6, the oxygen level was reset in the native oxygen chamber. The 
other flask will be cultured in an ambient oxygen tension incubator, at 19% oxygen. In addition, 
this experiement will contain an identical study as the previous except without growth factors. 
Upon passage on day 9, the cells will be seeded in 0.5mL of proliferation media containing the 
current Page Lab growth factor concentration at 20,000 cells per well and incubated for 24 hours 
at the respective oxygen tension. Next, the proliferation media will be removed, and the non-
adherent cells will be pelleted and resuspended in 0.5mL of differentiation media containing 2% 
adult horse serum, 1% ITS, and no growth factors. After 4 days, the cells will be stained for 
NCAM using the protocol described in Appendix A, and the myogenic index will be calculated 
as described in Immunocytochemistry Assay.   
Process Flow Diagram:  
 
Figure 8: Oxygen Tension Characterization 
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Adherent Cell and Non-Adherent Cell Behavior Characterization Objective: 
The objective of this study is to determine whether the non-adherent cell population 
exhibit a higher proliferation rate and are more often progressing through the cell cycle than the 
adherent cell population. 
Hypothesis:   
The non-adherent cells will exhibit a higher proliferation rate because the adherent cells 
have more cells that have terminally differentiated and fused. 
Experimental Design: 
In order to characterize the proliferation behavior of non-adherent cells, 60,000 cells were 
plated into a T25 Nunc flask and cultured until 60% confluence as shown in Figure 9 below. 
Upon passaging, 7,500 non-adherent cells and 7,500 adherent cells were plated separately into a 
4 well Nunc plate. Each of the cell samples were plated in 0.5mL of proliferation media 
containing current Page Lab growth factor concentrations with 5µL of BrdU labeling agent for 
48 hours. After 48 hours, the wells were stained for BrdU as previously described. 
Process Flow Diagram: 
 
Figure 9:  Adherent and Non-Adherent Behavior Characterization 
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4. Alternative Designs  
 With the client statement finalized and an approach determined, it becomes necessary to 
begin creating various designs in an effort to meet the constraints and objectives set forth. As 
there are many solutions that may be used to meet the demand of the client, it is important to 
understand the specific functions of the ideal design as a means of analyzing the multitude of 
options for completing the goal. Once designs and functions are determined, they are compared 
and analyzed for the best fit for the need of the client. 
4.1 Need Analysis 
 Before creating and brainstorming conceptual designs, it is essential to create a list of 
functions and specifications that must be met. The means of achieving each function were 
determined in order to incorporate them into the design. 
4.1.1 Design Functions 
 The functions that result from the client statement are compiled and analyzed to prioritize 
their importance and feasibility in relation to the conceptual and final design. The functions are 
as follows:  
1. Retain non-adherent cell population 
2. Provide a high growth surface area for scale-up 
3. Increase ease of media exchange 
4. Prevent cells from terminally differentiating 
Retain non-adherent cell population: In order for the design to meet the expectations of the 
client and maintain a high myogenic potential, it is important to retain the non-adherent cell 
population as well as the adherent population. This function is necessary to reduce the loss of 
cells that positively contribute to the myogenic potential of the culture. 
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Provide a high surface area for scale-up: It is necessary for the system to be cultured in a 
vessel that provides high surface area in order to reduce the amount of supplies, time, and labor 
that goes into passaging the cells. This allows the cost of the system to be reduced dramatically. 
Increase ease of media exchange: An important step in the cell culturing protocol is changing 
the media that the cells are suspended in. It is essential to be able to access and change the media 
in the system to continue culturing.  
Prevent cells from terminally differentiating: It is necessary to maintain a population that has 
not begun terminally differentiating. The process and system must be able to avoid terminal 
differentiation of the cells in order to meet the needs of the client. When a cell terminally 
differentiates, it is no longer capable of proliferating. This leads to a lower number of functional 
muscle cells. 
4.1.2 Design Specifications 
 Along with functions, there are also several specifications necessary for the design to 
meet in order for it to be successful. Through an analysis of the client statement and functions for 
the objectives determined, the following specifications were concluded: 
1. Maintain a myogenic potential of 30% or greater 
2. Provide at least 1000 cm2 of surface area for scale up 
 
Maintain a myogenic potential of 30% or greater: One of the most important objectives set 
forth by the client was the necessity of a high myogenic potential, maintaining a minimum of 
30%. This is a benchmark that must be attained in order for the cells to be functional enough to 
treat volumetric muscle loss. 
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Provide 1000 cm
2
 of surface area for scale up: For the process to improve upon current 
practices and prove feasible, the design must utilize a scale-up system. Currently, cells are 
cultured in a flask or dish with a surface area of 75cm
2
. In a scale-up, it is necessary increase the 
surface area, so the system requires less time and labor.  Reduced time and labor will reduce the 
cost of the system. 
4.1.3 Functions and Means Analysis 
To analyze the functions and decide on various means, a Functions-Means chart is 
utilized. With each function, possible means are determined that are capable of meeting the given 
functions. The following chart analyzes and displays the relations between the functions and 
means. 
Table 3: Functions-Means Chart 
Functions Means 
Retain non-adherent 
cell population 
 
Centrifuge 
media and 
resuspend 
pellet  
Media filter Sedimentation 
Provide a high surface 
area for scale-up 
(>1000 cm
2
) 
Roller bottle  Multi-tray 
vessel 
Microcarrier 
system 
Facilitate media 
exchange 
Communal 
vent and fill 
port 
Media filter Larger culture 
vessel 
Prevent cells from 
terminally 
differentiating 
Passage cells 
at 60% 
Increase 
surface area 
through 
expandable 
plates 
Low oxygen 
tension 
 
 Using the above chart, the possible means of meeting the specific functions are displayed 
and are used to create conceptual designs for the cell culture system. Various means are 
combined to find the dominant aspects for several designs that meet the needs of the client most 
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accurately. For the system to function properly, it must be able to retain both the non-adherent 
and the adherent cell populations in the culture. To allow for this, manual media exchange can be 
utilized. Using a centrifuge to pellet the non-adherent cells at the bottom of a 15 mL conical 
tube, they can be separated from the old media and resuspended in fresh media before being 
returned to the system. A related function is the facilitation of media exchange. A possible means 
of this function is the use of a communal port system to allow for the manual exchange of media. 
The scale-up system may use a connected port or tube that is capable of draining the media all at 
once. If this is done in a manual and controlled manner, then both populations will be 
maintained. To allow for the exchange, the system would also require a single fill port to provide 
media to the entire system. 
 It is also important for the system to be able provide a high surface area, so that it 
requires less labor and time. There are several methods of scale-up currently on the market. One 
is a roller bottle. This involves using a round container that is spun on a roller mill, to provide 
media to all the cells on the inner cylinder. Another means is the multi-tray vessel. This scale-up 
approach increases the surface area of the system using a shelf-like container for the cells. A 
third means of increasing the surface area is a microcarrier system. This system allows for cell 
adhesion on small particles that are suspended in the media, increasing the overall surface area.  
 The final function that is addressed with several means is preventing terminal 
differentiation. A possible means is being able to passage the culture when the confluence 
reaches approximately 60%. The confluence of 60% prevents the cells from differentiating as 
they would at a higher density. This allows for an earlier passage, not allowing a confluence that 
supports differentiation or fusion. Another means is increasing the surface area. Greater surface 
area permits higher cell counts before the confluence for passaging is reached. A final means of 
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deterring terminal differentiation is decreasing the oxygen tension of the system. A lower oxygen 
tension creates a hypoxic system that is supportive of proliferation instead of differentiation 
while still sub culturing at less than 60% confluence (Kook 2008).   
4.2 Conceptual Designs 
In process design, there are many aspects to a design that come into play. Various studies 
were designed to characterize the different parameters of the system, including growth factor 
concentrations, oxygen tension, and plating densities. With the characterizations that result, a 
proposed combination was added to a scale-up system to complete the design. Meeting the 
functions of the system, the ideal means were chosen and the following scale-up options that are 
capable of applying specific test results were created.   
4.2.1 Media Filter Culture Dish 
A media filter culture dish can be used to prevent non-adherent cells from being pipetted 
into the supernatant that is aspirated from the culture dish. This functions exactly as a 100mm 
diameter cell culture dish; however, the non-adherent cells are retained without a centrifugation 
step or extra time spent retaining the non-adherent cells. The design of the media filter culture 
dish is shown below. Media is removed from within the section filtered by a microfilter, and 
media containing cells is added into the large section of the plate. 
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Figure 10: Media Filter Culture Dish Solidworks Model 
4.2.2 Roller Bottle 
One of the proposed scale-up methods is the roller bottle. The roller bottle is a long 
cylindrical tissue culture treated polystyrene bottle that is continuously rolled in a horizontal axis 
at a designated rate in an incubator. The media is placed in the bottle through an individual 
opening. As the bottle slowly rolls, the cells attach. The cells suspended in the media moves 
along the surface allowing for a greater surface area to use a smaller volume of media. With the 
single opening, there is minimal exposure to the external environment as it is covered with a 
fastened cap with a sterile filter. The surfaces of the bottles are ridged to increase the surface 
area. The spinning makes the culture dynamic, which allows for better gas exchange and 
prevents the formation of a gradient (Rafiq 2013). 
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Figure 11: Roller Bottle (Park, 2008) 
4.2.3 Multi-tray vessel  
Another possible scale-up design is the multi-tray vessel. The multi-tray scale-up uses 
several layers to utilize surface area in a smaller, confined space. Using an enlarged flask, several 
layers are added within its walls that are connected in the bottom corner for media removal and 
addition. Though further media is necessary, there are several positive aspects of the system. 
There is no need for electrical assistance as it lays flat in an incubator. Also, the flask does not 
need a lot of space within an incubator. For media exchange, there is only one opening that is 
securely covered by a filtered cap. Media is filtered through a connecting port and is able to be 
collected and added from a single chamber, making exchange time efficient. 
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Figure 12: Multi-Layer Flask (Thermo Scientific) 
4.2.4 Microcarrier system 
A third conceptual design option for the scale-up is a microcarrier system. The system 
uses small particles that are placed in a bioreactor to promote adhesion. The particles in the 
bioreactor are mixed in the given media with the suspended cells, promoting cell-particle 
adhesion. The system increases the surface area by using particles as the adhesive surface. The 
number of particles can be controlled, which allows for manipulation of the system. Other 
benefits of the system result from the ability to control the scale-up system. Factors such as shear 
strength, particle seeding concentration, and continuous passaging allow for the design to be 
modified for the specific pilot study results (Tashiro et al., 2012). As such factors are able to be 
controlled, the system becomes more efficient. The seeding concentration allows for controlled 
population growth and density while the continuous passage allows the population to remain 
within constant media without exposing the cells to a bare environment or unnecessary 
chemicals. Also, with the varying physical properties of cells, the shear strength may be 
controlled to prevent unwanted stress.   
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Figure 13: Bioreactor/Microcarrier System (Yamaji, 2006) 
4.3 Selection of Final Design 
After creating three conceptual scale-up designs, a final design was chosen to best fit the 
need of the client. Analyzing the relationship between the costs and benefits with each, as well as 
analyzing the designs in relation to objectives and constraints, a final design was selected.  
4.3.1 Cost-Benefit Analysis  
In order to assist in the selection of a final design, a cost-benefit analysis was performed 
to determine which design alternative has the best benefit to cost ratio. The ideal design would 
best meet all of the desired criteria and would cost the least. Benefits of using a roller bottle 
include having a high surface area (850-1750 cm
2
), which allows for reduced time and labor. The 
media can be changed easily without losing the non-adherent cell population and the risk of 
contamination is the same as a standard cell culture flask. The cost for a case of twenty roller 
bottles is between $150 and $425 depending on the size (VWR International). This is relatively 
cheap compared to other scale-up options. It also requires a motorized device to spin the bottle. 
The multi-tray vessel is beneficial because it allows for a large amount of surface area (632-6320 
cm
2
) in a small total volume, the largest being 2000 milliliters. It requires the same media 
volume ratio, but it does not have to be motorized. The media can be changed easily through one 
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port. The cost for a case of six of these multi tray vessels ranges from $380 to $1500 depending 
on the size and number of chambers (VWR International). Finally, the microcarrier system 
allows for a higher surface area based on the seeding density of the microparticles in the 
bioreactor. The ability to control the various factors of the system makes it advantageous for 
modifying the reactor to fit the desired culture conditions. The cost of a bioreactor is around 
$230 and collagen microparticles are around $120 for 10g. The estimated total cost of this 
system is around $350.  
 Based on the cost-benefit analysis, the roller bottle is the best option.  It has the cheapest 
price per surface area and performs all the other desired functions. 
4.3.2 Design Evaluation Matrix 
 A Design Evaluation Matrix was used to analyze the various conceptual designs in 
relation to the previously determined objectives and constraints, three being the highest and zero 
being the lowest. 
Table 4: Design Evaluation Matrix 
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2 3 3 3 3 0 Y N Y 14 
 
              Following the evaluation matrix, it was found that the Roller Bottle scale-up system is 
the most feasible design alternative. Though the three designs coincided with most of the 
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objectives, the Roller Bottle best fit the objectives as it has the same effectiveness but is less 
effective. 
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5. Experimental Results 
 Before a final conclusion can be drawn and a final system design implemented, it is 
necessary to gather the results of the various characterization experiments designed. The results 
were used to determine the best design solution for the previously stated client statement.  The 
following data results from the previously mentioned characterization experiments.  
5.1 Growth Factor Characterization 
 To understand the impact the individual growth factors had on the cell culture, the 
population was split into six separate populations, each exposed to differing media lacking a 
different growth factor. Using the complete proliferation media with current Page Lab growth 
factor concentrations as a positive control, each population was exposed to the complete media 
without the concentration on one of the growth factors. Flask 1 contained media that excluded 
HGF while Flask 2 excluded IGF-1. The third and fourth flasks excluded EGF and FGF-2 
respectively. The negative control population was exposed to complete media without growth 
factors.  
5.1.1 Passaging 
 The various populations were allowed to proliferate for one passage. Once the population 
reached approximately 60% confluence, the population was passaged and replated at a lower 
density of 20,000 in 4-well plates. The following images correspond with the experimental 
groups at the first passage. 
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No HGF No IGF-1 No EGF 
   
No FGF-2 (+) Control (-) Control 
Figure 14: GF Characterization Passage 1 
5.1.2 Adherent Vs Non-Adherent Cell Counts 
 After allowing proliferation for a passage, the both the adherent and non-adherent 
populations of each group were counted and compared to show the effects on the ratio of the 
two.   
 50 
 
Figure 15: Cell Counts for Growth Factor Characterization Study After 1 Passage 
 
5.1.3 Immunocytochemistry and Myogenic Potential 
 Following a passage in the respective media for each experimental group, the populations 
were seeded at 20,000 cells into four well plates, allowing for two days of proliferation. After 
two days, the media was exchanged for differentiation media, as previously mentioned. 
Differentiation media was exchanged every two days over a course of eight days of 
differentiation. The groups were stained and imaged using Immunocytochemistry. The blue stain 
expresses the nuclei of the cells while the red expresses the NCAM. 
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No HGF No IGF No EGF 
   
No FGF (+) Control (-) Control 
Figure 16: NCAM Staining 
 Utilizing the fluorescent images for each of the experimental groups, along with both 
control groups, results were found through imaging software. Using the total number of nuclei 
and the NCAM positive nuclei, the myogenic potentials of each group were determined. The 
variance in the mean myogenic index among the groups is expressed in the following graph.  
 
Figure 17: Growth Factor Characterization 
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 In the cell population that was exposed to media that excluded HGF while following 
standard concentrations for the remaining growth factors, a mean myogenic index of 30.54 
±4.43% was found. Using media that neglected IGF-1 over three passages, a mean myogenic 
index of 21.47 ± 1.02% is the result. Removing EGF allowed for a mean myogenic index 28.91 
± 1.21%. The final experimental group without FGF-2 followed with an index of 25.61 ± 1.97%. 
The two controls also were analyzed to find average myogenic indices. The positive control gave 
a myogenic index of 31.43 ± 1.59% while the negative was 21.16 ± 1.94%. The following chart 
portrays the final results of the growth factor characterization.  
Condition Mean Myogenic 
Index (with SEM) 
No HGF 30.54 ±4.43% 
No IGF-1 21.47 ± 1.02% 
No EGF 28.91 ± 1.21%. 
No FGF-2 25.61 ± 1.97% 
(+) control 31.43 ± 1.59% 
(-) control 21.16 ± 1.94% 
Table 5: Table of Average Myogenic Potential 
 With the results that are concluded from the experiment, a statistical analysis was used to 
determine significance. In relation to the negative control group, it was found that the group 
without EGF was statistically different with a p-value of 0.026. The no IGF-1 group was 
statistically different from the positive control with a p-value of 0.002. The two controls were 
statistically different with p-values of 0.006.  
5.1.4 Cell Surface Area 
 To determine the extent to which cells are stressed, the surface area of each imaged cell 
were determined by means of imaging software. Using the average surface area for each group, 
the effect each individual had on the elongation and stress of cells amongst groups were found. 
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Figure 18: Average Cell Surface Area for the Removal of Each Individual Growth Factor 
For the analysis of surface area, the only statistically significant result was the no FGF-2 
group in relation to the positive control. All other comparison had p-values of higher than 0.05. 
 
5.2 Oxygen Tension Characterization  
 To characterize the difference culturing cells in the ambient oxygen conditions of a 
incubator and a low oxygen environment with 5% O2, the study was conducted with identical 
populations being cultured in both environments. After two passages in their respective 
conditions, the experimental and control groups were imaged prior to passage. 
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5% O2 with GF 5% O2 without GF 
  
Ambient O2 with GF Ambient O2 without GF 
Figure 19: Qualitative Images for Oxygen Tension Characterization 
 With the qualitative data presented in the images at passaging, the low oxygen tension 
shows a higher retaining of non-adherent cells when cultured in growth factor media. The control 
in ambient oxygen with growth factor had both adherent and non-adherent cells as well. Both 
non-growth factor groups were showed to be stressed as represented by the elongated shape of 
the cells.    
5.1.1 Adherent Vs Non-Adherent Cell Counts 
 After allowing proliferation for a passage, the both the adherent and non-adherent 
populations of each group were counted and compared to show the effects on the ratio of the 
two.   
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Figure 20:Cell Counts for Oxygen Tension Characterization 
5.2.2 Myogenic Potential 
 Aside from the qualitative data, the growth factor culture in low oxygen had 
approximately 111,250 cells that were adherent and 19,375 non-adherent cells. The ambient 
growth factor group had 83, 750 adherent cells and 31,250 non-adherent cells. For the non-
growth factor groups, the count for non-adherent cells were both too low to accurately count, 
proving to be less than 5,000 cells each. The low oxygen group without growth factors had 
97,500 cells while the ambient oxygen contained 105,000 adherent cells. Following the cells 
counts, the groups were stained for NCAM and the myogenic potential was calculated.  
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5% O2 with GF 5% O2 without GF 
  
Ambient O2 with GF Ambient O2 without GF 
Figure 21: Immunocytochemistry Staining for NCAM for Oxygen Tension Characterization 
 Fluorescent microscopy was used to image the four groups after staining for NCAM. The 
blue represents the nuclei while the red stains NCAM. With the images, the myogenic indexes 
were calculated.  
 
Figure 22: Myogenic Indices for Oxygen Tension Characterization 
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The low oxygen environment with growth factors had a myogenic index of   33.47 ± 1.93% 
while the ambient conditions with growth factors had an index of 30.16 ± 1.26%. The non-
growth factor group in low oxygen has a myogenic index of 22.14 ± 3.21%. The group without 
growth factors in ambient oxygen had a myogenic index of 19.14 ± 0.65%. Indexes were also 
found for the low oxygen proliferated groups that were differentiated in ambient oxygen.  
Table 6: Mean Myogenic Indices for Oxygen Tension Characterization 
Condition Mean Myogenic 
Index (with SEM) 
5% O2 w/ GF 33.47 ± 1.93% 
5% O2 w/o GF 22.14 ± 3.21%   
5% O2 w/ GF  
(ambient 
differentiation) 
34.56 ± 0.13% 
19% O2 w/ GF 30.16 ± 1.26% 
19% O2 w/o GF 19.14 ± 0.65% 
5% O2 w/o GF  
(ambient 
differentiation) 
23.66 ± 4.91% 
 With the results of the oxygen tension characterization, a statistical significance was 
found between 5% O2 with growth factors and ambient oxygen with growth factors having a p-
value of 0.026. Resulting in a p-value of 0.002, there is also a difference between ambient 
oxygen with growth factors and ambient oxygen without growth factors showing significance.  
5.2.3 Cell Tension 
To determine the effect of oxygen concentration on the cell tension, the surface area of the 
imaged cells were found. With a less stressed cell being characterized as having a smaller surface 
area, the following chart shows the results of the oxygen tension experiment as it relates to the 
state of stress for the cells. 
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Figure 23: Average Cell Surface Area At 5% and 19% Oxygen Tension 
 With a p-value of 0.012, the low oxygen with growth factors proved significantly 
different than the low oxygen without growth factors.  
5.3 Adherent and Non-Adherent Behavior Characterization 
In determining whether the non-adherent cell population has a higher rate of proliferation 
over the adherent population, a characterization study that utilizes BrdU staining is used. It is 
also used to determine which progresses through the cell cycle at a more progressive rate. Cells 
of the same population and passage were placed into four well plates at a density of 
approximately 7,500 cells per well. The cells were separated into three groups. One well 
contained only the adherent population. Another well contained only the non-adherent 
population. The final group contained a combination of both populations.  BrdU staining was 
used to stain the nuclei that are present in a proliferative state while all nuclei are stained with 
Hoechst.   
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BrdU A – t=0 Hrs BrdU NA – t=0 Hrs 
  
BrdU A – t=48 Hrs BrdU Na – t=48 Hrs 
Figure 24: BrdU Assay for t=0 and t=48 hrs 
5.3.1 BrdU Labeled at t=0 hours 
 When the population was initially split into the three groups, the BrdU labeling agent was 
added. The labeling agent was first added at t=0 hours. After forty-eight hours, the BrdU 
quantification assay was followed to obtain the percentage of cells proliferating.  
 
Figure 25: Graph of BrdU Labeled at t=0 hrs 
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For the groups that were stained at t=0 hours, vary results were found. For the group that 
contained only the adherent cells from the previous population, approximately 23.39 ± 15.54% 
of the cells were in a proliferative state on average. The mean proliferation percentage of the 
non-adherent cells was found to be approximately 27.28 ± 1.29%.  
Table 7: Table of BrdU Labeled at t=0 hrs 
BrdU labeled at t=0 
Population Mean Proliferation % 
(with SEM) 
Adherent 23.39 ± 15.54% 
Non-
adherent 
27.28 ± 1.29% 
 
5.3.2 Adherent Cells BrdU Labeled at t=48 hours 
 After forty-eight hours of proliferation, the original all adherent population left from the 
original split into an adherent and non-adherent population. With these populations, 7,500 cells 
per well were again seeded for the adherent, non-adherent, and the mixed populations.  At t=48 
hours, the labeling agent was again added. The cells labelled another 48 hours before staining. 
Each population gave way to a varied mean proliferation percentage. 
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Figure 26: Graph of Adherent cells BrdU at t=48 hrs 
The results of the final BrdU assay ranged among the three groups. For the adherent cells 
of the t=48 hours population, the mean proliferation was 32.63 ± 4.22%. The non-adherent was 
slightly lower with a mean proliferation percentage of 29.40 ± 3.31%.  
Table 8: Table of Adherent Cells BrdU Labeled at t=48 hrs 
Adherent cells BrdU labeled at 
t=48h 
Population Mean Proliferation 
% (with SEM) 
Adherent 32.63 ± 4.22% 
Non-
Adherent 
29.40 ± 3.31% 
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6. Discussion 
 This chapter will identify the significance of the results, as well as the limitations of what 
can be concluded from the results. It takes a critical look at the uniqueness of this project, and 
also determines the impact that the project could have on a number of societal factors. 
6.1 Results Analysis 
 It is necessary to analyze the results in order to confirm or reject the hypotheses of each 
of the tests. To analyze the results, t-tests were performed in order to quantify the significance. 
The team determined if there were any significant differences between the test groups.  
6.1.1 Growth Factor Characterization 
 The team looked at the results for the myogenic indices obtained from our growth factor 
characterization study. It was hypothesized that the removal of any of the growth factors would 
decrease the myogenic potential of the culture. Based on this, the only growth factor that caused 
a statistically significant change when removed from the culture was IGF-1. The average size of 
the cells was also measured before the cells were differentiated. This showed that the removal of 
FGF-2 caused a significant difference in the cell size. The cells became more stressed and 
resembled the population with no growth factors. There were limitations encountered when 
performing the growth factor characterization study. Due to the number of samples, some of the 
standard errors were relatively large.  
6.1.2 Oxygen Tension Characterization 
 Cells that were passaged at low and ambient oxygen were compared to see if the 
condition produced significant results. After staining for NCAM, it was shown that there was a 
significant difference in myogenic potential between the 5 percent oxygen population and the 
ambient oxygen population. Both populations contained growth factors in Page lab 
concentrations. When cultured at lower oxygen tension, the culture maintained a higher 
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myogenic potential. There was no significant correlation between the level of oxygen tension and 
the average surface area of the cells.  
6.1.3 Adherent Versus Non-adherent Behavior Characterization 
 The group analyzed the results from the BrdU study in order to determine if there is a 
statistically significant conclusion that can be drawn between the non-adherent state of the cells 
and the proliferation. It was hypothesized that the well with non-adherent cells would have the 
higher proliferation percentage, and the well with adherent cells would have the lower 
proliferation percentage. No statistical difference was identified between the different 
populations. Therefore, there was no significant difference in proliferation for any of the wells. 
These results were limited by the sample size that was tested, which did not allow these results to 
produce a significant conclusion. 
6.2 Impact Analysis 
In the group’s pursuit for an innovative way to culture human primary skeletal muscle 
cells for prolonged periods of time while maintaining a high myogenic index, it was also 
important to analyze the impacts the cell culture system might have on multiple areas within our 
society and the world in general. The following section will address the economical, 
environmental, political, and ethical impacts the system could have in today’s world. It is also 
paramount to understand the societal influence, health and safety issues as well as the 
sustainability and manufacturability of the cell culture system the group has designed. The group 
took into consideration every one of the topics keeping in mind that technology is always 
moving forward and if a designed product negates this progression, it cannot be considered a 
successful product. 
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6.2.1 Economics 
One of the first impacts to consider is the economic impact our cell culture system has in 
our current society. The cell therapy industry is a market where there is significant demand. Our 
system is part of a process to successfully treat volumetric muscle loss using a biopsy. Enabling 
a therapy for volumetric muscle loss will change the industry and investors could see substantial 
revenue from this in the future. According to an editorial from futuremedicine.com, the cell 
therapy industry had global sales of $410 million back in 2008 and that number is predicted to 
increase to $5.1 billion by the end of this year (Mason, 2011). 
6.2.2 Environmental 
Our design does not directly affect the environment, however, if the tools used during this 
process are not disposed of according to the guidelines set by our institution, those by products 
could potentially end up harming the environment. Because there are non-renewable and non-
biodegrable products being used throughout the whole process, taking precaution by reading 
guidelines and safety protocols before disposing of those materials will minimize the effect on 
the environment. Furthermore, the purpose of the scale-up is to reduce the flasks’ surface area to 
media ratio. This would also minimize the effect our final design would have on the 
environment.  
6.2.3 Societal Influence 
It was previously mentioned that the cell therapy industry is a market where demand for 
treatments of different diseases is increasing while the treatments themselves are not being 
developed as fast. For instance, in 2009 it was estimated that approximately 2.5 million patients 
in the United States could have benefited from a cell-based therapy. Because of the need for 
newly developed therapies, only 6,000 patients were able to receive an advanced cell-based 
therapy (Mason, 2009). We hope that our cell culture system will further the development of a 
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new cell-based therapy system for volumetric muscle loss. This would have an enormous impact 
in society as millions of patients could see themselves benefited from a volumetric muscle loss 
cell therapy. 
6.2.4 Political Ramifications 
Our cell culture system will most likely not have any political ramifications, as these 
procedures are performed in-vitro in a closed environment. Since this type of treatment is 
relatively new, developing nations and even some developed nations might not see this treatment 
as a feasible one at the moment so it is not expected for our system to have a big impact on the 
global market. 
6.2.5 Ethical Concern 
Because the origin of the primary muscle skeletal cells the group used for this experiment 
was from a biopsy, we believe there are minimal ethical concerns. This type of research was 
done with the purpose of enabling a therapy for volumetric muscle loss. Fetal-Clone III is 
composed of processed bovine serum and this may raise ethical concerns as to how the serum 
was harvested from the fetus (Thermo Scientific, 2013). 
6.2.6 Health and Safety Issue 
This cell culture system has the potential to further the progress to enable a therapy to 
treat volumetric muscle loss. Individuals suffering from trauma to extremities will see 
themselves benefitted as well as individuals suffering from muscular dystrophies and 
compartment syndrome. This cell-based therapy would negate the need for autografts that has 
limitations such as donor site morbidity, loss of functionality, and volume deficiency. Cell-based 
therapies could have the potential to create more jobs in the industry while improving the lives of 
millions of patients. Along with Pharmaceuticals, biologics, and medical devices, cell therapies 
could become the fourth pillar of healthcare (Mason, 2009).  
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Figure 27: Pillars of Healthcare (Mason, 2009) 
6.2.7 Manufacturability 
The group designed a cell culture system to more effectively grow primary skeletal 
muscle cells while maintaining a high myogenic index under specific conditions. The conditions 
under which our final system was designed are fairly simple to replicate, however, they are very 
specific and steps need to be followed carefully. 
6.2.8 Sustainability 
The group utilized medium components such as Fetal-Clone III serum which derives 
from bovine serum. There are individuals who are opposed to the use of a fetus for medical 
purposes and do not agree with the purpose of our research. What we are trying to do is help 
people whose lives have been affected by an accident or disease. All components of our cell 
culture systems were used following the protocols and guidelines of out institution. We hope our 
product will give people an opportunity to experience a different way of life than the one they 
currently know.  
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Chapter 7: Final Design and Validation 
 Upon completion of the experiments characterizing individual system parameters, the 
experimental results were analyzed and applied to a final in vitro scale-up system.  The final cell 
culture system will incorporate effective oxygen tension, growth factor concentrations, and cell 
kinetics into a biocompatible, quantifiable system that improves the proliferation rate of human 
primary muscle cells while maintaining a myogenic potential of greater than 30%.  
7.1 Cell Culture  
 In order to assess the final design of the scaled cell culture system, assays will be 
performed using hSkm-1201 cells as previously mentioned in Cell Culture Methods. After a 
population of 500,000 cells was retrieved from the Page Lab, cells were proliferated in complete 
proliferation media containing current Page Lab growth factor concentrations in T75 Nunc flasks 
in order to generate enough cells for testing. Upon passaging at 60%, cells were replated in T75 
flasks for further proliferation, plated at specific densities with set conditions for experimental 
testing, or frozen at 500,000cells/mL stored in liquid nitrogen in order to maintain a stock of 
cells. 
7.2 Assessment of Roller Bottle Scale-Up 
 The feasibility, cost, and effectiveness of the use of a roller bottle for scale up will be 
determined by testing a dynamic culture in a 1050cm
2
 Nunc roller bottle compared to a 
controlled, static culture in a T75 Nunc flask. In order to perform this testing, 1050cm
2
 Nunc 
roller bottles were purchased from VWR. A roller bottle and flask will be cultured 
simultaneously in proliferation media with current Page Lab growth factor concentrations for one 
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passage with the surface areas, media volumes, and cell plating densities listed in the table 
below. 
Table 9: Surface Area, Media Volume, and Cell Numbers for Scale-Up Testing 
 Roller Bottle Flask 
Surface Area (cm
2
) 1050 25 
Media Volume (mL) 180 3 
Cell Plating Density (total cells) 1,260,000 30,000 
 
 Both populations will be cultured for one passage with routine media exchange every 3 
days. When cells are ready to be trypsinized, adherent and non-adherent cell populations will be 
counted. 
7.3 Testing the Final Design 
 The final design was tested for scalability by comparing cell culture populations in a 
1050cm
2
 Nunc roller bottle and a T25cm
2
 Nunc flask. Cells were plated at the same cell density 
in terms of cells/cm
2
 in the roller bottle and flask. At t=0, 1,260,000 and 30,000 cells were plated 
in the roller bottle and flask, respectively, and continued for one passage. The roller bottle was 
placed on a roller mill rotating at 1rpm inside the incubator for 24 hours in order for cells to seed. 
For the remaining duration of the cell culture, the roller mill spun at 2rpm. Media was routinely 
changed every 3 days, and on t=9days, the roller bottle and flask were passaged and non-
adherent and adherent cell populations were counted using a hemocytometer. The resultant 
counts are shown in Table 14 below. The roller bottle yielded 74.26% that the equivalent surface 
area, 1050cm
2
, of T25cm
2
 flasks yielded. 
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Table 10: Cell Counts for Final Design Scale-Up Testing 
 1050cm
2 
Roller Bottle T25cm
2
 Flask 
Adherent Cells 2,274,355 73,500 
Non-Adherent Cells 788,424 24,700 
Total Cells 3,062,779 98,200 
7.4 Design of Scaled Up System 
 The roller bottle system was scaled up for potential application in generating a large cell 
population to fill a critical size defect. The current system and the final design system were 
scaled up to generate a cell population of at least 1,000,000,000 cells for regeneration of a 
muscle defect of 15cm
3
. Figure 16 below contains a flow chart displaying the materials and cell 
numbers used in each passage. 
 
Figure 28: Flow Charts Comparing the Final Design System and the Current Cell Culture System 
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 In addition to the use of 1050cm
2
 roller bottles, the final scaled up system also applies the 
parameters of oxygen tension and growth factor combinations in order to improve the benefits of 
the system. The removal of HGF from the proliferation media reduces the cost of 500mL by 
$7.20 while providing statically similar results to the proliferation media with all current Page 
Lab growth factor concentrations. Furthermore, the results of the oxygen tension characterization 
suggested that 5% oxygen tension improves the proliferation rate of the cell population. Oxygen 
tension and the dynamics of the roller bottle culture, including rpm, media volume, and plating 
densities can be further characterized in future work to increase the proliferation rate of cells 
within the roller bottle to cells Based on these parameters, a cost-benefit analysis was performed 
comparing the current system with the scalable final design.  
7.5 Cost-Benefit Analysis of Final Design 
 The cost-benefit analysis comparing the current cell culture system with the final design 
of the improved system evaluated cost of materials, media, media components, and labor is 
shown in the table below. Culture materials are based on pricing from VWR International for 
Nunc vessels and Celltreat centrifuge tubes. Nunc T75cm
2
 flasks and 1050cm
2
 cost $3.59 and 
$11.00, respectively (VWR International). Celltreat 15mL and 50mL centrifuge tubes cost $0.21 
and $0.24, respectively (Celltreat Scientific Products). Labor costs for media exchange were 
calculated as $2,210.14 for 118 hours for media change in the current system versus $468.25 for 
25 hours in the final system. This calculation was based on 10 minutes to change media in 6 
flasks and 10 media to change media in 2 roller bottles. Labor costs for passages were calculated 
as $7,548.19 for 403 hours for passaging within the current system versus $1,217.45 for 65 hours 
in the final system. This calculation was based on 20 minutes to passage 3 flasks and 10 media to 
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change media in 2 roller bottles. The average salary used to calculate lab technician labor cost 
was $18.73 per hour (Chron, 2014). 
Table 11: Cost-Benefit Analysis of the Roller Bottle System Versus the Current Cell Culture System 
 1050cm
2
 Roller Bottle 
System 
T75cm
2
 Flask 
Media $6,098.83 
($41.32/500mL 
without HGF) 
$4,456.08 
($48.52/500mL) 
Labor ($18.73/hr) $1,685.70 $9,758.33 
Culture Vessel $2,849 $13,017.34 
Centrifuge Tubes $642.24 $3257.32 
Total: $11,275.77 $30,489.07 
mL of Media 73,800 45,920 
Number of Culture 
Vessels 
259 Roller Bottles 
 
3626 T75 Flasks 
Number of Centrifuge 
Tubes 
2,676 50mL 15,512 15mL 
Total Time 18.5 days 18.5 days 
 
 In generating a population of at least 1,000,000,000 cells, the roller bottle system costs 
$11,275.77 in comparison with $30,489.07 for the current T75cm
2
 flask system. The final scaled 
up system can more effective generate large cell population without significant differences in 
maintaining myogenic potential. 
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8. Conclusion 
 Upon completion of the characterization experiments and the analysis of the results, it 
was concluded that there is an effect on the cell culture of human muscle cells in relation to 
growth factor concentration and the presence of an adherent and non-adherent population. From 
the results portrayed by the growth factor characterization, it is possible to conclude that the 
removal of one or more of the standard growth factors decreases the overall myogenic potential 
in relation to the current complete media and growth factor standards set forth by Page Lab. In 
relation to myogenic potential, there is no statistically significant difference among the various 
growth factor concentrations. The largest qualitative impacts were seen with the removal of 
FGF-2 and EGF, where minimal change occurred with the lack of HGF. The exclusion of FGF-2 
lead to stressed cells and early differentiation. This was confirmed by measurements of cell 
surface area, which proved that there was a statistical difference in the cell size compared to the 
positive control. There is minimal difference when comparing the positive control and the 
experimental group with media that excluded HGF. From the growth factor characterization 
experiment, the designed system using media that contains IGF-1, EGF, and FGF-2 has no 
significant difference from the current system. The removal of HGF produces the same effect but 
reduces the overall cost of the system.  
 Based on the results from the oxygen tension characterization experiment, it can be 
concluded that lower oxygen tension has a positive effect on the myogenic potential of a culture 
of human skeletal muscle cells. This along with a roller bottle scale-up system can produce 
favorable myogenic cultures, while allowing for reduced labor and material cost. 
 In future experiments to further address the system design, there are several 
recommendations that should be taken into consideration. When designing and completing the 
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characterization experiments, it is essential to have multiple passages so that the cells can be 
exposed to the variable conditions for an extended period of time. This will allow researchers to 
see the long-term effects of the altered culture conditions. After the culturing adjustments, it 
would also be useful to test other growth factor concentrations based on the qualitative results of 
the growth factor characterization. Finally, looking further into the relationship between the 
adherent and non-adherent population is important to better design the system. With the 
proposed design and further investigation into the future recommendations, a cell-based therapy 
system for volumetric muscle loss progresses further down the path towards clinical application. 
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Appendix A: Protocols 
 
NCAM Immunocytochemistry  
(Biomedical Engineering Department, Worcester Polytechnic Institute, 2013) 
Materials 
PBS (MediaTech Cat # 21-040-CM, VWR Cat # 45000-448) 
Tween-20  
DPBS+ Dulbeco’s phosphate buffered saline with Ca/Mg, MediaTech Cat # 21-030-CV , VWR, 
Cat. # 45000-430) 
FBS (use blocking FBS, stored at -20C), or any bovine serum, or serum derived from species of 
the secondary antibody 
Alexafluor-488 conjugated anti-mouse IgG (Invitrogen), or Alexafluor-568 conjugated anti-
mouse IgG (Invitrogen) 
Antimyosin antibody (mouse IgG), MF20 from Developmental Studies Hybridoma Bank, stored 
at 4 C 
Fomaldehyde (3.7% in DPBS+) 
 PBS with 0.05% Tween-20 (PBS/Tween) 
Cells grown in 24-well plates 
Glycerol DNase, RNase, protease free (Shelton Scientific, Cat # IB15672, VWR Cat # IB15762) 
 Hoechst 33342 (EMD Cat # 382065-100MG, VWR Cat # 80056-706) 
Procedure 
1. Aspirate culture medium and wash cells with DPBS for 1 min. 
2. Aspirate DPBS and add 500 l/well 3.7% formaldehyde and let stand for 10 min.   
3. Aspirate formaldehyde and add 1.0 ml/well PBS 
4. Aspirate PBS and add blocking solution (PBS with 3% FBS or appropriate serum) at 150 
μl per well and incubate at RT for 30 min. 
5. Aspirate blocking solution and add primary antibody (1:500 dilution in PBS/Tween) at 
150 μl per well and incubate at RT for 30 min.  Secondary antibody-only controls will 
skip this step. 
6. Aspirate primary antibody and  wash 4X with PBS for 3 min each wash. 
7. Aspirate PBS and add secondary antibody (diluted 1:500 in PBS/Tween) at 150 μl/well 
and incubate for 30 min. 
8. Aspirate secondary antibody solution and wash 4X with PBS.  If nuclear counterstain is 
desired, add Hoechst 33342 at 0.5 μg/ml in PBS to last wash and incubate for 10 min.  
Aspirate Hoechst and add 1 ml/well PBS.  
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9. Cells are ready for observation by fluorescence microscopy.  Plates can be stored at 4C 
wrapped in foil to protect from light.  If long term storage is desired replace PBS with 
PBS containing 0.1% Na-Azide to prevent bacterial growth. 
 
 
DAPI staining 
Counterstaining Adherent cells for fluorescence microscopy 
(Biomedical Engineering Department, Worcester Polytechnic Institute, 2013) 
Sample Preparation 
Use appropriate fixation protocol. DAPI staining is normally performed after all other staining. 
Note that fixation and permeabilization of the sample is not necessary for counterstaining with 
DAPI. 
Counterstaining Protocol 
1. Equilibrate the sample briefly with phosphate-buffered saline (PBS). 
2. Dilute the DAPI stock solution to 300 nM in PBS. Add approximately 300 µL of this 
dilute DAPI staining solution to the coverslip preparation, making certain that the cells 
are completely covered. 
3. Incubate for 1-5 minutes 
4. Rinse the sample several times in PBS. Drain excess buffer from the coverslip and 
mount. It is recommended to use a mounting medium with an anti-fade reagent. 
5. View the sample using a fluorescence microscope with the appropriate filters. 
 
 
Feeding Cells 
(Biomedical Engineering Department, Worcester Polytechnic Institute, 2013) 
Feeding cells refers to removing cell culture medium and replacing it with fresh cell culture medium.  
NOTE: Pre-warm medium to 37°C in a water bath prior to adding it to the cells.  
1. Remove half the volume of medium from the culture and put into 15 mL conical tube.  
2. Centrifuge at 200G for 6 minutes in order to pellet cells at the bottom. 
3. Aspirate old medium using a Pasteur pipet attached to a vaccum trap. (Be careful to avoid 
aspirating the pellet of cells) 
4. Resuspend the pellet in fresh medium (same volume that was removed). 
5. Using serological pipet, return cell suspension to the culture dish. 
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Passaging Cells 
(Biomedical Engineering Department, Worcester Polytechnic Institute, 2013) 
When cells are 60-70% confluent, remove medium with serological pipet and put into 15 mL conical 
tube. Wash cells with 1X DPBS(-) (without Ca
++
/Mg
++
) by adding and then aspirating PBS.  
Confluent: Refers to the area of cell coverage on the plate. If cells are covering  
~ 70% of the surface of the plate, they are 70% confluent.  
NOTE: Use ½ the volume of PBS to rinse as there was medium in the dish (e.g., a 100 mm dish is 
fed 10 mL medium, therefore use 5 mL PBS per rinse).  
 Trypsinize cells by adding 0.05% trypsin EDTA (~ 3 mL for a 100 mm plate) for 3-5 mins.  
Plates may be returned to the incubator while trypsinizing.  
NOTE: Dilute trypsin stock 1:5 in sterile DPBS(-) to make a working solution of  
0.05% to add to the cells.  
 
NOTE: Serum in culture medium inactivates trypsin.  
7.5 ml fresh medium in a new 100 mm dish = a 1:4 split/passage). Alternately, seed a specific number of 
cells in the total volume prescribed for a particular culture dish.  
 
 
Cell Counting 
(Biomedical Engineering Department, Worcester Polytechnic Institute, 2013) 
For most experiments, it is important to use a consistent plating density (the number of cells added to the 
culture per area of the culture dish they are plated on). Rather than plating an arbitrary volume of cell 
suspension as described in “Passaging Cells” above, it is necessary to count the number of cells per unit 
volume in the cell suspension, and determine the volume of cells to plate to achieve the desired plating 
density. Below is a depiction of the counting area of a typical hemocytometer. The cells are trypsinized 
and resuspended as described above. A small volume of cells (~ 12 microliters) is added to the counter at 
the indentation in the bottom glass and allowed to fill the area by capillary action under the coverglass. 
Do not force-fill the counting chamber.  
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1. Count all cells in the four corner sections (light colored squares below each consisting of 16 squares) as 
shown in Figure 1 and 2.  
2. Divide the total by 4 to obtain the average number of cells per square.  
3. The volume of each square is 100 nl (nano liters) or 1/10,000 ml. Calculate total count per ml as 
follows. Make sure to take into account the original dilution of cells (if applicable) and the dilution used 
during trypan blue staining.  
4. Calculate the total cell count by multiplying the above figure with the total volume of cell suspension 
from which the sample was drawn.   
To increase the cell density of the suspension or to concentrate the cells for freezing (see below), 
centrifuge the cell suspension at low speed (200g for 5 minutes) to pellet them. Gently aspirate the 
supernatant and resuspend the cell pellet in the appropriate medium at the appropriate volume.  
 
 
Collagen Coating 
(Biomedical Engineering Department, Worcester Polytechnic Institute, 2013) 
1. Add 250 ul of collagen, poly L-lysine and gelatin stock solutions to the corresponding wells 
and close the lid. 
2. Swirl the plate to ensure that the coatings cover the entire surface. 
3. Allow coating to proceed for 30 minutes to 1 hour inside the hood. 
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4. After coating, aspirate the solutions from every well. 
5. Add 500 µl sterile water to the poly L-lysine wells. This wash step is only for the poly L- 
lysine wells. DO NOT WASH THE OTHER WELLS. Aspirate and discard the water. 
Repeat the rinse two more times (for a total of 3 rinses). 
6. Leave the plate with the lid open inside the hood. 
7. Allow the wells to dry for 20-30 minutes inside the hood. 
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Appendix B: Lab Spreadsheet 
Date Population Passage # 
Confluenc
e 
Cell Count 
Media 
(Diff/Prolif
) 
Notes 
1/11/14 1 4 
 
250,000 P 
Thawed cells; 
Plated in two 
T75s 
 
2 4 
 
250,000 P 
 
1/13/14 1 
 
20% 
 
P 
Media Change 
(MC) 
 
2 
 
20% 
 
P MC 
1/15/14 1 
 
30% 
 
P MC 
 
2 
 
30% 
 
P MC 
1/17/14 1 
 
40% 
 
P MC 
 
2 
 
40% 
 
P MC 
1/20/14 1 5 80% 975,000 P 
Over-
confluent, 
reseeded at 
200k 
 
2 5 70% 750,000 P 
Reseeded at 
200k cells 
1/22/14 1 
 
50% 
 
P MC 
 
2 6 50% 600,000 
P(GF 
study) 
Used for 
growth factor 
study 
1/24/14 1 
 
60% 750,000 Freeze 
Poor cell 
quality; froze 
500k cells 
 
2 
 
30% 
 
P(GF 
study) 
MC 
1/26/14 2 
 
40% 
 
P(GF 
study) 
MC 
1/28/14 2 
 
50% 
 
P(GF 
study) 
MC 
1/30/14 2 7 60% 78,000 
P(GF 
study) 
First GF study 
passage 
2/1/14 2 
 
20% 
 
P(GF 
study) 
MC 
2/3/14 2 
 
30% 
 
P(GF 
study) 
MC 
2/5/14 2 
 
40% 
 
P(GF 
study) 
MC 
2/7/14 2 
 
50% 
 
P(GF 
study) 
MC 
2/9/14 2 8 60% 81,000 P(GF Second GF 
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study) study passage. 
2/11/14 2 
 
10% 
 
P(GF 
study) 
MC 
2/13/14 2 
 
20% 
 
P(GF 
study) 
MC 
2/16/14 2 
 
40% 
 
P(GF 
study) 
MC 
 
3 4 
 
500,000 P 
Thawed cells; 
Plated in T75 
2/18/14 2 9 50% 43,000 
P(GF 
study) 
Third passage 
into 4 well 
plates 
 
3 
 
40% 
 
P MC 
2/20/14 
     
Made 
Differentiation 
Media 
2/21/14 2 
 
70% 
 
D 
Media Change 
to Diff. media 
 
3 5 60% 560,000 P 
Split into two 
T75 flasks (3 
+ 4) 
2/23/14 2 
   
D MC 
 
3 
 
40% 
 
P MC 
 
4 
 
30% 
 
P MC 
2/25/14 2 
   
D MC 
2/26/14 3 6 60% 570,000 P 
BrdU study 
started 
 
4 
 
40% 
 
P MC 
2/27/14 2 
   
D MC 
2/28/14 3 
 
40% 
 
P MC 
 
4 
 
50% 
 
P MC 
      
Got results for 
GF study and 
first part of 
BrdU 
3/1/14 3 
 
40% 
 
P MC 
3/2/14 4 6 60% 500,000 Freeze 
Froze 500k 
cells 
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Appendix C: Imaging  
 
Growth Factor Characterization 
No HGF: 
Bright Field:  
 
    
 
Florescent: 
 
    
 
Surface Area:  
 
   
 
No IGF-1 
Bright Field: 
 88 
 
    
 
Florescent: 
 
    
 
Surface Area:  
 
   
 
No EGF: 
Bright Field:  
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Florescent: 
 
    
 
Surface Area:  
 
   
 
No FGF-2: 
Bright Field: 
 
    
 
Florescent: 
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Surface Area: 
 
   
 
Control (+): 
Bright Field: 
 
    
 
Florescent: 
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Surface Area: 
 
   
 
Control (-): 
Bright Field: 
 
    
 
Florescent: 
 
    
 
Surface Area: 
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Oxygen Tension Characterization:  
5% O2 w/ GF:  
At passage: 
 
  
 
Bright Field: 
 
    
 
Florescent: 
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Surface Area: 
 
  
 
5% O2 w/o GF: 
At passage: 
 
  
 
Bright Field: 
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Florescent: 
 
    
 
Surface Area: 
 
  
 
19% O2 w/ GF: 
At passage: 
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Bright Field: 
 
   
 
Florescent: 
 
   
 
Surface Area: 
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19% O2 w/o GF: 
At passage: 
 
  
 
Bright Field: 
 
    
 
Florescent:  
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Surface Area: 
 
  
 
 
BrdU: 
Adherent: 
 
    
 
Non-Adherent:  
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